Andrea Scozzafava

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9754/publications.pdf

Version: 2024-02-01

648 papers	42,611 citations	1530 106 h-index	4978 167 g-index
690 all docs	690 docs citations	690 times ranked	16428 citing authors

#	Article	IF	Citations
1	Carbonic anhydrase inhibitors. Medicinal Research Reviews, 2003, 23, 146-189.	5.0	1,126
2	Carbonic anhydrase inhibitors. Bioorganic and Medicinal Chemistry, 1999, 7, 2397-2406.	1.4	808
3	Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. Cancer Research, 2011, 71, 3364-3376.	0.4	662
4	Anticancer and Antiviral Sulfonamides. Current Medicinal Chemistry, 2003, 10, 925-953.	1.2	646
5	Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Letters, 2004, 577, 439-445.	1.3	620
6	Carbonic anhydrases as targets for medicinal chemistry. Bioorganic and Medicinal Chemistry, 2007, 15, 4336-4350.	1.4	521
7	Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opinion on Therapeutic Patents, 2000, 10, 575-600.	2.4	485
8	Non-Zinc Mediated Inhibition of Carbonic Anhydrases: Coumarins Are a New Class of Suicide Inhibitors. Journal of the American Chemical Society, 2009, 131, 3057-3062.	6.6	457
9	Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16233-16238.	3.3	451
10	Ureido-Substituted Benzenesulfonamides Potently Inhibit Carbonic Anhydrase IX and Show Antimetastatic Activity in a Model of Breast Cancer Metastasis. Journal of Medicinal Chemistry, 2011, 54, 1896-1902.	2.9	443
11	Unexpected Nanomolar Inhibition of Carbonic Anhydrase by COX-2-Selective Celecoxib:Â New Pharmacological Opportunities Due to Related Binding Site Recognition. Journal of Medicinal Chemistry, 2004, 47, 550-557.	2.9	426
12	Protease inhibitors of the sulfonamide type: Anticancer, antiinflammatory, and antiviral agents. Medicinal Research Reviews, 2003, 23, 535-558.	5.0	385
13	Deciphering the Mechanism of Carbonic Anhydrase Inhibition with Coumarins and Thiocoumarins. Journal of Medicinal Chemistry, 2010, 53, 335-344.	2.9	363
14	Carbonic Anhydrase Inhibitors. Synthesis of Water-Soluble, Topically Effective, Intraocular Pressure-Lowering Aromatic/Heterocyclic Sulfonamides Containing Cationic or Anionic Moieties:â€‰ Is the Tail More Important than the Ring?. Journal of Medicinal Chemistry, 1999, 42, 2641-2650.	2.9	278
15	Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2013, 23, 705-716.	2.4	273
16	Carbonic Anhydrase Activators:â€‰ X-ray Crystallographic and Spectroscopic Investigations for the Interaction of Isozymes I and II with Histamine,. Biochemistry, 1997, 36, 10384-10392.	1.2	269
17	Biochemical Characterization of CA IX, One of the Most Active Carbonic Anhydrase Isozymes. Journal of Biological Chemistry, 2008, 283, 27799-27809.	1.6	258
18	Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents?. Bioorganic and Medicinal Chemistry, 2001, 9, 703-714.	1.4	252

#	Article	IF	Citations
19	Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 217-223.	1.0	251
20	Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opinion on Therapeutic Patents, 2013, 23, 725-735.	2.4	246
21	Sulfonamides and Sulfonylated Derivatives as Anticancer Agents. Current Cancer Drug Targets, 2002, 2, 55-75.	0.8	243
22	Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opinion on Therapeutic Patents, 2002, 12, 217-242.	2.4	243
23	Glycosyl Coumarin Carbonic Anhydrase IX and XII Inhibitors Strongly Attenuate the Growth of Primary Breast Tumors. Journal of Medicinal Chemistry, 2011, 54, 8271-8277.	2.9	228
24	Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors:â€‰ Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II, and IV, and N-Hydroxysulfonamides Inhibit Both These Zinc Enzymes. Journal of Medicinal Chemistry, 2000, 43, 3677-3687.	2.9	224
25	Highly Active Antiretroviral Therapy: Current State of the Art, New Agents and Their Pharmacological Interactions Useful for Improving Therapeutic Outcome. Current Pharmaceutical Design, 2005, 11, 1805-1843.	0.9	222
26	Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 841-845.	1.0	221
27	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamidesâ€”a new target for the design of antitumor and antiglaucoma drugs?. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 963-969.	1.0	212
28	Dithiocarbamates Strongly Inhibit Carbonic Anhydrases and Show Antiglaucoma Action in Vivo. Journal of Medicinal Chemistry, 2012, 55, 1721-1730.	2.9	211
29	Characterization of CA XIII, a Novel Member of the Carbonic Anhydrase Isozyme Family. Journal of Biological Chemistry, 2004, 279, 2719-2727.	1.6	210
30	Carbonic anhydrase IX: A new druggable target for the design of antitumor agents. Medicinal Research Reviews, 2008, 28, 445-463.	5.0	210
31	Carbonic Anhydrase Inhibitors. Design of Fluorescent Sulfonamides as Probes of Tumor-Associated Carbonic Anhydrase IX That Inhibit Isozyme IX-Mediated Acidification of Hypoxic Tumorsâ€. Journal of Medicinal Chemistry, 2005, 48, 4834-4841.	2.9	205
32	Polyamines Inhibit Carbonic Anhydrases by Anchoring to the Zinc-Coordinated Water Molecule. Journal of Medicinal Chemistry, 2010, 53, 5511-5522.	2.9	205
33	Sulfonamides: a patent review (2008 â€“ 2012). Expert Opinion on Therapeutic Patents, 2012, 22, 747-758.	2.4	201
34	Carbonic Anhydrase Inhibitors:â€‰ X-ray and Molecular Modeling Study for the Interaction of a Fluorescent Antitumor Sulfonamide with Isozyme II and IX. Journal of the American Chemical Society, 2006, 128, 8329-8335.	6.6	200
35	Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chemical Communications, 2010, 46, 8371.	2.2	200
36	Sulfocoumarins (1,2-Benzoxathiine-2,2-dioxides): A Class of Potent and Isoform-Selective Inhibitors of Tumor-Associated Carbonic Anhydrases. Journal of Medicinal Chemistry, 2013, 56, 293-300.	2.9	199

#	Article	IF	Citations
37	Carbonic Anhydrase Inhibitors. Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents, 2001, 1, 61-97.	0.2	195
38	Sulfamates and their therapeutic potential. Medicinal Research Reviews, 2005, 25, 186-228.	5.0	191
39	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1005-1009.	1.0	189
40	Carbonic anhydrase inhibitors: Interactions of phenols with the 12 catalytically active mammalian isoforms (CA Iâ€“XIV). Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1583-1587.	1.0	186
41	Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiotherapy and Oncology, 2009, 92, 423-428.	0.3	185
42	Carbonic Anhydrase Inhibitors. The Mitochondrial Isozyme VB as a New Target for Sulfonamide and Sulfamate Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 7860-7866.	2.9	179
43	Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2315-2320.	1.0	176
44	Therapeutic potential of sulfamides as enzyme inhibitors. Medicinal Research Reviews, 2006, 26, 767-792.	5.0	173
45	Rosmarinic acid inhibits some metabolic enzymes including glutathioneS-transferase, lactoperoxidase, acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase isoenzymes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1698-1702.	2.5	173
46	Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Medicinal Chemistry, 2014, 6, 1149-1165.	1.1	172
47	Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1-39.	2.5	167
48	Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opinion on Therapeutic Patents, 2004, 14, 667-702.	2.4	159
49	Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opinion on Therapeutic Patents, 2006, 16, 1627-1664.	2.4	158
50	Carbonic Anhydrase Inhibitors:Â Stacking with Phe131 Determines Active Site Binding Region of Inhibitors As Exemplified by the X-ray Crystal Structure of a Membrane-Impermeant Antitumor Sulfonamide Complexed with Isozyme II. Journal of Medicinal Chemistry, 2005, 48, 5721-5727.	2.9	157
51	Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiotherapy and Oncology, 2007, 83, 367-373.	0.3	157
52	Carbonic anhydrase inhibitors: The Î²-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3585-3594.	1.0	157
53	Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. Chemical Communications, 2012, 48, 1868.	2.2	157
54	Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiotherapy and Oncology, 2011, 99, 424-431.	0.3	156

#	Article	IF	Citations
55	Carbonic anhydrase inhibitors. Part 37. Novel classes of isozyme I and II inhibitors and their mechanism of action. Kinetic and spectroscopic investigations on native and cobalt-substituted enzymes. European Journal of Medicinal Chemistry, 1996, 31, 1001-1010.	2.6	155
56	Nonaromatic Sulfonamide Group as an Ideal Anchor for Potent Human Carbonic Anhydrase Inhibitors:â€‰ Role of Hydrogen-Bonding Networks in Ligand Binding and Drug Design. Journal of Medicinal Chemistry, 2002, 45, 3583-3587.	2.9	154
57	Carbonic Anhydrase Inhibitors:â€‰ DNA Cloning and Inhibition Studies of the Î±-Carbonic Anhydrase from Helicobacter pylori, A New Target for Developing Sulfonamide and Sulfamate Gastric Drugs. Journal of Medicinal Chemistry, 2006, 49, 2117-2126.	2.9	154
58	Carbonic Anhydrase Inhibitors:Â Synthesis of Water-Soluble, Aminoacyl/Dipeptidyl Sulfonamides Possessing Long-Lasting Intraocular Pressure-Lowering Properties via the Topical Route1. Journal of Medicinal Chemistry, 1999, 42, 3690-3700.	2.9	153
59	Metalloantibiotics: Synthesis and Antibacterial Activity of Cobalt(II), Copper(II), Nickel(II) and Zinc(II) Complexes of Kefzol. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 79-84.	2.5	153
60	Carbonic anhydrase inhibitors - Part 49: Synthesis of substituted ureido and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I. European Journal of Medicinal Chemistry, 1998, 33, 83-93.	2.6	152
61	7,8-Disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7255-7258.	1.0	152
62	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms Iâ€“XV. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5050-5053.	1.0	151
63	Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 869-873.	1.0	150
64	Carbonic Anhydrase Inhibitors. Design of Selective, Membrane-Impermeant Inhibitors Targeting the Human Tumor-Associated Isozyme IX. Journal of Medicinal Chemistry, 2004, 47, 2337-2347.	2.9	149
65	Antimetastatic Effect of Sulfamate Carbonic Anhydrase IX Inhibitors in Breast Carcinoma Xenografts. Journal of Medicinal Chemistry, 2012, 55, 5591-5600.	2.9	149
66	Carbonic Anhydrase Inhibitors:Â Synthesis of Membrane-Impermeant Low Molecular Weight Sulfonamides Possessing in Vivo Selectivity for the Membrane-Bound versus Cytosolic Isozymes1. Journal of Medicinal Chemistry, 2000, 43, 292-300.	2.9	147
67	Bacterial protease inhibitors. Medicinal Research Reviews, 2002, 22, 329-372.	5.0	147
68	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 231-234.	1.0	147
69	Metal binding and antibacterial activity of ciprofloxacin complexes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2005, 20, 303-307.	2.5	147
70	Carbonic Anhydrase Inhibitors:â€‰ Clash with Ala65 as a Means for Designing Inhibitors with Low Affinity for the Ubiquitous Isozyme II, Exemplified by the Crystal Structure of the Topiramate Sulfamide Analogue. Journal of Medicinal Chemistry, 2006, 49, 7024-7031.	2.9	147
71	Zinc Complexes of Benzothiazole-derived Schiff Bases with Antibacterial Activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 259-263.	2.5	146
72	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 971-976.	1.0	145

#	Article	IF	Citations
73	Characterization of cobalt(II) bovine carbonic anhydrase and of its derivatives. Journal of the American Chemical Society, 1978, 100, 4873-4877.	6.6	144
74	Carbonic Anhydrase Inhibitors:Â Water-Soluble 4-Sulfamoylphenylthioureas as Topical Intraocular Pressure-Lowering Agents with Long-Lasting Effects. Journal of Medicinal Chemistry, 2000, 43, 4884-4892.	2.9	143
75	Carbonic Anhydrase Inhibitors. Inhibition of Mitochondrial Isozyme V with Aromatic and Heterocyclic Sulfonamides. Journal of Medicinal Chemistry, 2004, 47, 1272-1279.	2.9	143
76	The effect of caffeic acid phenethyl ester (CAPE) on metabolic enzymes including acetylcholinesterase, butyrylcholinesterase, glutathione S-transferase, lactoperoxidase, and carbonic anhydrase isoenzymes I, II, IX, and XII. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1095-1101.	2.5	142
77	Carbonic Anhydrase Inhibitors:â€‰ Anticonvulsant Sulfonamides Incorporating Valproyl and Other Lipophilic Moieties. Journal of Medicinal Chemistry, 2002, 45, 312-320.	2.9	141
78	Carbonic Anhydrase Inhibitors. Inhibition of Tumor-Associated Isozyme IX by Halogenosulfanilamide and Halogenophenylaminobenzolamide Derivativesâ€. Journal of Medicinal Chemistry, 2003, 46, 2187-2196.	2.9	141
79	Proton NOE studies on dicopper(II) dicobalt(II) superoxide dismutase. Inorganic Chemistry, 1989, 28, 4650-4656.	1.9	140
80	Carbonic Anhydrase Inhibitors:â€‰ Perfluoroalkyl/Aryl-Substituted Derivatives of Aromatic/Heterocyclic Sulfonamides as Topical Intraocular Pressure-Lowering Agents with Prolonged Duration of Action. Journal of Medicinal Chemistry, 2000, 43, 4542-4551.	2.9	139
81	Carbonic Anhydrase Inhibitors. A General Approach for the Preparation of Water-Soluble Sulfonamides Incorporating Polyaminoâ˜Polycarboxylate Tails and of Their Metal Complexes Possessing Long-Lasting, Topical Intraocular Pressure-Lowering Properties. Journal of Medicinal Chemistry, 2002, 45, 1466-1476.	2.9	138
82	Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 2197-2204.	2.9	138
83	Designing of Novel Carbonic Anhydrase Inhibitors and Activators. Current Medicinal Chemistry Cardiovascular and Hematological Agents, 2004, 2, 49-68.	1.7	138
84	Carbonic anhydrase inhibitors: Inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3828-3833.	1.0	138
85	Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3102-3108.	1.0	137
86	ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chemical Communications, 2007, , 156-158.	2.2	137
87	Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle, 2013, 12, 1791-1801.	1.3	136
88	Carbonic anhydrase inhibitors â€" Part 29 1: Interaction of isozymes I, II and IV with benzolamide-like derivatives. European Journal of Medicinal Chemistry, 1998, 33, 739-751.	2.6	135
89	Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors. Current Medicinal Chemistry, 2007, 14, 2734-2748.	1.2	132
90	Carbonic anhydrase inhibitors â€" Part 52. Metal complexes of heterocyclic sulfonamides: A new class of strong topical intraocular pressure-lowering agents in rabbits. European Journal of Medicinal Chemistry, 1998, 33, 247-254.	2.6	131

#	Article	IF	Citations
91	Carbonic Anhydrase Activators. Activation of Isozymes I, II, IV, VA, VII, and XIV withL- andD-Histidine and Crystallographic Analysis of Their Adducts with Isoform II: Engineering Proton-Transfer Processes within the Active Site of an Enzyme. Chemistry - A European Journal, 2006, 12, 7057-7066.	1.7	131
92	COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents. Mini-Reviews in Medicinal Chemistry, 2004, 4, 625-632.	1.1	130
93	Carbonic Anhydrase Activators. Activation of Isoforms I, II, IV, VA, VII, and XIV with l- and d-Phenylalanine and Crystallographic Analysis of Their Adducts with Isozyme II:â€‰ Stereospecific Recognition within the Active Site of an Enzyme and Its Consequences for the Drug Design. Journal of Medicinal Chemistry, 2006, 49, 3019-3027.	2.9	128
94	A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects. Bioorganic and Medicinal Chemistry, 2015, 23, 1828-1840.	1.4	126
95	Carbonic anhydrase: An insight into the zinc binding site and into the active cavity through metal substitution. , 1982, , 45-92.		124
96	Unsymmetrical 1,1â€²-disubstituted Ferrocenes: Synthesis of Co(ii), Cu(ii), Ni(ii) and Zn(ii) Chelates of Ferrocenyl -1-thiadiazolo-1â€²-tetrazole, -1-thiadiazolo-1â€²-triazole and -1-tetrazolo-1â€²-triazole with Antimicrobial Properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 261-266.	2.5	124
97	The Coumarin-Binding Site in Carbonic Anhydrase Accommodates Structurally Diverse Inhibitors: The Antiepileptic Lacosamide As an Example and Lead Molecule for Novel Classes of Carbonic Anhydrase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 850-854.	2.9	123
98	Novel therapies for glaucoma: a patent review 2007 â€“ 2011. Expert Opinion on Therapeutic Patents, 2012, 22, 79-88.	2.4	121
99	An Î±-carbonic anhydrase from the thermophilic bacterium Sulphurihydrogenibium azorense is the fastest enzyme known for the CO2 hydration reaction. Bioorganic and Medicinal Chemistry, 2013, 21, 1465-1469.	1.4	121
100	Carbonic anhydrase inhibitors: guaiacol and catechol derivatives effectively inhibit certain human carbonic anhydrase isoenzymes (hCA I, II, IX and XII). Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 586-591.	2.5	121
101	Carbonic anhydrase inhibitors: Inhibition of mammalian isoforms Iâ€“XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorganic and Medicinal Chemistry, 2008, 16, 7424-7428.	1.4	120
102	Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiffâ€™s bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3096-3101.	1.0	115
103	Glaucoma and the Applications of Carbonic Anhydrase Inhibitors. Sub-Cellular Biochemistry, 2014, 75, 349-359.	1.0	114
104	Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 575-582.	1.0	112
105	Single-crystal ESR spectra of copper(II) complexes with geometries intermediate between a square pyramid and a trigonal bipyramid. Inorganic Chemistry, 1978, 17, 3194-3197.	1.9	111
106	Proton NMR spectroscopy and the electronic structure of the high potential iron-sulfur protein from Chromatium vinosum. Journal of the American Chemical Society, 1991, 113, 1237-1245.	6.6	111
107	Novel coumarins and 2-thioxo-coumarins as inhibitors of the tumor-associated carbonic anhydrases IX and XII. Bioorganic and Medicinal Chemistry, 2012, 20, 2266-2273.	1.4	109
108	Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. Expert Opinion on Therapeutic Patents, 2001, 11, 221-259.	2.4	107

#	Article	IF	Citations
109	Crystal structure of the blue multicopper oxidase from the white-rot fungus Trametes trogii complexed with p-toluate. Inorganica Chimica Acta, 2008, 361, 4129-4137.	1.2	107
110	Carbonic Anhydrase Inhibitors. Cloning, Characterization, and Inhibition Studies of a New Î²-Carbonic Anhydrase from Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2009, 52, 3116-3120.	2.9	107
111	Crystal structure of a blue laccase from Lentinus tigrinus: evidences for intermediates in the molecular oxygen reductive splitting by multicopper oxidases. BMC Structural Biology, 2007, 7, 60.	2.3	105
112	Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2267-2271.	1.0	104
113	Cloning, Characterization, and Inhibition Studies of a Î²-Carbonic Anhydrase from Brucella suis. Journal of Medicinal Chemistry, 2010, 53, 2277-2285.	2.9	104
114	Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: Solution and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry, 2014, 22, 334-340.	1.4	104
115	Design and Synthesis of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDsâ€“CAIs) for the Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2017, 60, 1159-1170.	2.9	104
116	Antiviral Sulfonamide Derivatives. Mini-Reviews in Medicinal Chemistry, 2004, 4, 189-200.	1.1	103
117	Carbonic Anhydrase Inhibitors: The First Selective, Membrane-Impermeant Inhibitors Targeting the Tumor-Associated Isozyme IX.. ChemInform, 2004, 35, no.	0.1	103
118	DNA Cloning, Characterization, and Inhibition Studies of an Î±-Carbonic Anhydrase from the Pathogenic Bacterium Vibrio cholerae. Journal of Medicinal Chemistry, 2012, 55, 10742-10748.	2.9	103
119	Carbonic Anhydrase Inhibitor Coated Gold Nanoparticles Selectively Inhibit the Tumor-Associated Isoform IX over the Cytosolic Isozymes I and II. Journal of the American Chemical Society, 2008, 130, 16130-16131.	6.6	102
120	The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents. Current Pharmaceutical Design, 2008, 14, 649-654.	0.9	101
121	Carbonic Anhydrase Inhibitors:Â Hypoxia-Activatable Sulfonamides Incorporating Disulfide Bonds that Target the Tumor-Associated Isoform IXâ€. Journal of Medicinal Chemistry, 2006, 49, 5544-5551.	2.9	100
122	Carbonic anhydrase inhibitors: Cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorganic and Medicinal Chemistry, 2007, 15, 7229-7236.	1.4	100
123	X-ray structure of the first `extremo-Î±-carbonic anhydrase', a dimeric enzyme from the thermophilic bacteriumSulfurihydrogenibium yellowstonenseYO3AOP1. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 1150-1159.	2.5	100
124	Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with l-histidine as a platform for the design of stronger activators. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 5136-5141.	1.0	99
125	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5427-5433.	1.0	98
126	Carbonic anhydrase inhibitors: Inhibition of the Î²-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with simple anions. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5066-5070.	1.0	98

#	Article	IF	Citations
127	Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins: Structure, Function and Bioinformatics, 2009, 74, 164-175.	1.5	97
128	Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII evidence a new binding mode within the enzyme active site. Bioorganic and Medicinal Chemistry, 2011, 19, 1381-1389.	1.4	97
129	Dithiocarbamates are strong inhibitors of the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 859-862.	1.0	97
130	Carbonic anhydrase inhibitors - Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?. European Journal of Medicinal Chemistry, 2000, 35, 867-874.	2.6	96
131	The impact of hydroquinone on acetylcholine esterase and certain human carbonic anhydrase isoenzymes (hCA I, II, IX, and XII). Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 941-946.	2.5	96
132	Molecular Cloning, Characterization, and Inhibition Studies of the Rv1284 Î²-Carbonic Anhydrase from Mycobacterium tuberculosis with Sulfonamides and a Sulfamate. Journal of Medicinal Chemistry, 2009, 52, 2226-2232.	2.9	94
133	Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II â€˜selectiveâ€™ inhibitor celecoxib. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 437-442.	1.0	93
134	Carbonic anhydrase activators: l-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 628-635.	1.0	93
135	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 689-721.	2.5	93
136	Xanthates and Trithiocarbonates Strongly Inhibit Carbonic Anhydrases and Show Antiglaucoma Effects in Vivo. Journal of Medicinal Chemistry, 2013, 56, 4691-4700.	2.9	91
137	Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity. Bioorganic and Medicinal Chemistry, 2004, 12, 2717-2726.	1.4	90
138	Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry, 2011, 19, 3105-3119.	1.4	90
139	Biochemical properties of a newÎ±-carbonic anhydrase from the human pathogenic bacterium,Vibrio cholerae. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 23-27.	2.5	90
140	Investigation of Cu2Co2SOD and its anion derivatives. Proton NMR and electronic spectra. Journal of the American Chemical Society, 1985, 107, 4391-4396.	6.6	89
141	Cloning, Characterization, and Sulfonamide and Thiol Inhibition Studies of an Î±-Carbonic Anhydrase fromTrypanosoma cruzi, the Causative Agent of Chagas Disease. Journal of Medicinal Chemistry, 2013, 56, 1761-1771.	2.9	89
142	Carbonic Anhydrase Inhibitors. DNA Cloning, Characterization, and Inhibition Studies of the Human Secretory Isoform VI, a New Target for Sulfonamide and Sulfamate Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 381-388.	2.9	88
143	Carbonic anhydrase inhibitors. Sulfonamide diuretics revisitedâ€”old leads for new applications?. Organic and Biomolecular Chemistry, 2008, 6, 2499.	1.5	88
144	Inhibition of the alpha- and beta-carbonic anhydrases from the gastric pathogenHelycobacter pyloriwith anions. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 388-391.	2.5	88

#	Article	IF	Citations
145	Carbonic anhydrase inhibitors: Inhibition of the Î²-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates. Bioorganic and Medicinal Chemistry, 2009, 17, 1158-1163.	1.4	86
146	The β-Carbonic Anhydrases from Mycobacterium tuberculosis as Drug Targets. Current Pharmaceutical Design, 2010, 16, 3300-3309.	0.9	85
147	Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 6001-6006.	1.0	83
148	Discovery of Low Nanomolar and Subnanomolar Inhibitors of the Mycobacterial Î²-Carbonic Anhydrases Rv1284 and Rv3273. Journal of Medicinal Chemistry, 2009, 52, 4063-4067.	2.9	82
149	Carbonic anhydrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 837-840.	1.0	81
150	Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action?. Bioorganic and Medicinal Chemistry, 2005, 13, 483-489.	1.4	81
151	Carbonic anhydrase activators: The first X-ray crystallographic study of an adduct of isoform I. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5152-5156.	1.0	81
152	Carbonic Anhydrase Activation and the Drug Design. Current Pharmaceutical Design, 2008, 14, 708-715.	0.9	81
153	Antibacterial Schiff Bases of Oxalyl-hydrazine/diamide Incorporating Pyrrolyl and Salicylyl Moieties and of Their Zinc(II) Complexes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 1-7.	2.5	80
154	Carbonic Anhydrase Inhibitors:â€‰ Inhibition of Transmembrane, Tumor-Associated Isozyme IX, and Cytosolic Isozymes I and II with Aliphatic Sulfamates. Journal of Medicinal Chemistry, 2003, 46, 5471-5477.	2.9	79
155	The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5825-5828.	1.0	79
156	A new Î²-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. Bioorganic and Medicinal Chemistry, 2011, 19, 1172-1178.	1.4	79
157	Secondary and tertiary sulfonamides: a patent review (2008 â€“ 2012). Expert Opinion on Therapeutic Patents, 2013, 23, 203-213.	2.4	79
158	Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3283-3290.	1.0	78
159	New Zinc Binding Motifs in the Design of Selective Carbonic Anhydrase Inhibitors. Mini-Reviews in Medicinal Chemistry, 2006, 6, 921-936.	1.1	78
160	Anion inhibition studies of an Î±-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5630-5634.	1.0	77
161	Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus. Neuropharmacology, 2017, 118, 148-156.	2.0	77
162	Arylsulfonyl-N,N-diethyl-dithiocarbamates: a novel class of antitumor agents. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1887-1891.	1.0	76

#	Article	IF	Citations
163	Fungal laccase, cellobiose dehydrogenase, and chemical mediators: Combined actions for the decolorization of different classes of textile dyes. Bioresource Technology, 2008, 99, 7003-7010.	4.8	76
164	Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase IIâ€“trithiocarbonate adductâ€”An inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 474-478.	1.0	76
165	Inhibition of the Î²-carbonic anhydrase from Streptococcus pneumoniae by inorganic anions and small molecules: Toward innovative drug design of antiinfectives?. Bioorganic and Medicinal Chemistry, 2011, 19, 243-248.	1.4	76
166	Secondary/tertiary benzenesulfonamides with inhibitory action against the cytosolic human carbonic anhydrase isoforms I and II. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 294-298.	2.5	76
167	Design of Zinc Binding Functions for Carbonic Anhydrase Inhibitors. Current Pharmaceutical Design, 2008, 14, 615-621.	0.9	75
168	Thioxocoumarins Show an Alternative Carbonic Anhydrase Inhibition Mechanism Compared to Coumarins. Journal of Medicinal Chemistry, 2016, 59, 462-473.	2.9	75
169	Carbonic anhydrase inhibitors â€” Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV. European Journal of Medicinal Chemistry, 1998, 33, 577-594.	2.6	74
170	Carbonic Anhydrase Activators:â€‰Design of High Affinity Isozymes I, II, and IV Activators, Incorporating Tri-/Tetrasubstituted-pyridinium-azole Moieties. Journal of Medicinal Chemistry, 2002, 45, 504-510.	2.9	74
171	The sulfamide motif in the design of enzyme inhibitors. Expert Opinion on Therapeutic Patents, 2006, 16, 27-47.	2.4	74
172	The first activation study of a bacterial carbonic anhydrase (CA). The thermostable Î±-CA from Sulfurihydrogenibium yellowstonense YO3AOP1 is highly activated by amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6324-6327.	1.0	73
173	Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three Î²-class carbonic anhydrases from Mycobacterium tuberculosis. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 384-387.	2.5	73
174	Inhibition of the Î²-class carbonic anhydrases fromMycobacterium tuberculosiswith carboxylic acids. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 392-396.	2.5	73
175	Which Carbonic Anhydrases are Targeted by the Antiepileptic Sulfonamides and Sulfamates?. Chemical Biology and Drug Design, 2009, 74, 317-321.	1.5	72
176	Characterization of the first beta-class carbonic anhydrase from an arthropod (Drosophila) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 Td Biochemistry, 2010, 11, 28.	4.4	72
177	Antibacterial Co(II), Cu(II), Ni(II) and Zn(II) Complexes of Thiadiazole Derived Furanyl, Thiophenyl and Pyrrolyl Schiff Bases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 117-122.	2.5	71
178	Proton NMR spectra of oxidized high-potential iron-sulfur protein (HiPIP) from Rhodocyclus gelatinosus. A model for oxidized HiPIPs. Inorganic Chemistry, 1991, 30, 4517-4524.	1.9	70
179	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2347-2352.	1.0	70
180	Carbonic Anhydrase Inhibitors:Â Synthesis and Inhibition of Cytosolic/Membrane-Associated Carbonic Anhydrase Isozymes I, II, and IX with Sulfonamides Incorporating Hydrazino Moieties. Journal of Medicinal Chemistry, 2005, 48, 2121-2125.	2.9	70

#	Article	IF	Citations
181	Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4376-4381.	1.0	70
182	Inhibition studies with anions and small molecules of two novel Î²-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3591-3595.	1.0	70
183	7-Substituted-sulfocoumarins are isoform-selective, potent carbonic anhydrase II inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 4502-4510.	1.4	70
184	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 337-341.	1.0	69
185	Anticonvulsant 4-Aminobenzenesulfonamide Derivatives with Branched-Alkylamide Moieties: X-ray Crystallography and Inhibition Studies of Human Carbonic Anhydrase Isoforms I, II, VII, and XIV. Journal of Medicinal Chemistry, 2011, 54, 3977-3981.	2.9	69
186	Anion inhibition studies of the fastest carbonic anhydrase (CA) known, the extremo-CA from the bacterium Sulfurihydrogenibium azorense. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7142-7145.	1.0	69
187	Carbonic anhydrase activators: Human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1177-1180.	1.0	68
188	Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-Î±-d-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 225-229.	1.0	68
189	The extremo-Î±-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium azorense is highly inhibited by sulfonamides. Bioorganic and Medicinal Chemistry, 2013, 21, 4521-4525.	1.4	68
190	Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. Bioorganic and Medicinal Chemistry, 2000, 8, 2145-2155.	1.4	67
191	An Update in the Development of HIV Entry Inhibitors. Current Topics in Medicinal Chemistry, 2007, 7, 1273-1289.	1.0	67
192	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamideâ€“isozyme II adduct. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2567-2573.	1.0	67
193	The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian Î±-carbonic anhydrase isoforms. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4102-4106.	1.0	67
194	Protease Inhibitors:Â Synthesis of Potent Bacterial Collagenase and Matrix Metalloproteinase Inhibitors IncorporatingN-4-Nitrobenzylsulfonylglycine Hydroxamate Moieties. Journal of Medicinal Chemistry, 2000, 43, 1858-1865.	2.9	66
195	Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases. Chemical Communications, 2012, 48, 8177.	2.2	66
196	Novel Aromatic/Heterocyclic Sulfonamides and Their Metal Complexes as Inhibitors of Carbonic Anhydraseisozymes I, II and IV. Journal of Enzyme Inhibition and Medicinal Chemistry, 1997, 12, 37-51.	0.5	65
197	Purification, biochemical properties and substrate specificity of a catechol 1,2-dioxygenase from a phenol degradingAcinetobacter radioresistens. FEBS Letters, 1997, 416, 61-64.	1.3	65
198	Carbonic anhydrase activators: Kinetic and X-ray crystallographic study for the interaction of d- and l-tryptophan with the mammalian isoforms Iâ€“XIV. Bioorganic and Medicinal Chemistry, 2008, 16, 8373-8378.	1.4	65

#	Article	IF	Citations
199	Carbonic Anhydrase Inhibitors: Aromatic Sulfonamides and Disulfonamides Act as Efficient Tumor Growth Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 597-610.	0.5	64
200	Biochemical characterization of the Î³-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis, PgiCA. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 532-537.	2.5	64
201	Cloning, characterization and anion inhibition study of the Î´-class carbonic anhydrase (TweCA) from the marine diatom Thalassiosira weissflogii. Bioorganic and Medicinal Chemistry, 2014, 22, 531-537.	1.4	64
202	Carbonic Anhydrase Activators:â€‰ High Affinity Isozymes I, II, and IV Activators, Incorporating a Î²-Alanyl-histidine Scaffold. Journal of Medicinal Chemistry, 2002, 45, 284-291.	2.9	63
203	Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3593-3596.	1.0	63
204	Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: solution and crystallographic investigations. Bioorganic and Medicinal Chemistry, 2010, 18, 4873-4878.	1.4	63
205	A highly catalytically active Î³-carbonic anhydrase from the pathogenic anaerobe Porphyromonas gingivalis and its inhibition profile with anions and small molecules. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4067-4071.	1.0	62
206	Nuclear relaxation in the magnetic coupled system Cu2Co2SOD. Histidine-44 is detached upon anion binding. Journal of the American Chemical Society, 1987, 109, 2328-2334.	6.6	61
207	The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents. Current Topics in Medicinal Chemistry, 2007, 7, 849-854.	1.0	61
208	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorganic and Medicinal Chemistry, 2009, 17, 1214-1221.	1.4	61
209	5- and 6-Membered (thio)lactones are prodrug type carbonic anhydrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 267-270.	1.0	61
210	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 573-578.	1.0	60
211	Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1787-1791.	1.0	59
212	Carbonic Anhydrase Inhibitors: Schiff's Bases of Aromatic and Heterocyclic Sulfonamides and their Metal Complexes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 263-267.	2.5	59
213	Carbonic anhydrase inhibitors: topical sulfonamide antiglaucoma agents incorporating secondary amine moieties. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 673-676.	1.0	58
214	Carbonic anhydrase inhibitors. Inhibition of the zinc and cobalt $gamma;-class enzyme from the archaeon Methanosarcina thermophila with anions. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3327-3331.	1.0	58
215	Carbonic anhydrase catalyzes cyanamide hydration to urea: is it mimicking the physiological reaction?. Journal of Biological Inorganic Chemistry, 1999, 4, 528-536.	1.1	57
216	Phosphodiesterase 5 Inhibitors - Drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles. Current Pharmaceutical Design, 2006, 12, 3459-3465.	0.9	57

#	Article	IF	Citations
217	Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4681-4685.	1.0	57
218	Jahn-Teller distortions of tris(ethylenediamine)copper(II) complexes. Inorganic Chemistry, 1977, 16, 1973-1976.	1.9	56
219	Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 367-372.	1.0	56
220	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal Î²-carbonic anhydrase from Candida albicans with sulfonamides. Bioorganic and Medicinal Chemistry, 2009, 17, 4503-4509.	1.4	56
221	Carbonic Anhydrase Inhibitors. Comparison of Chlorthalidone and Indapamide X-ray Crystal Structures in Adducts with Isozyme II: When Three Water Molecules and the Ketoâ^'Enol Tautomerism Make the Difference. Journal of Medicinal Chemistry, 2009, 52, 322-328.	2.9	56
222	Inhibition studies of the Î²-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates. Bioorganic and Medicinal Chemistry, 2011, 19, 5023-5030.	1.4	56
223	A Class of Sulfonamides with Strong Inhibitory Action against the Î±-Carbonic Anhydrase from Trypanosoma cruzi. Journal of Medicinal Chemistry, 2013, 56, 5773-5781.	2.9	56
224	Six-coordinate copper complexes wlth g<g in the solid state. Coordination Chemistry Reviews, 1979, 29, 67-84.	9.5	55
225	Carbonic anhydrase inhibitors. Part 43. Schiff bases derived from aromatic sulfonamides: towards more specific inhibitors for membrane-bound versus cytosolic isozymes. European Journal of Medicinal Chemistry, 1997, 32, 445-452.	2.6	55
226	Targeting Cysteine Residues of Biomolecules: New Approaches for the Design of Antiviral and Anticancer Drugs. Current Medicinal Chemistry, 2002, 9, 1167-1185.	1.2	55
227	New selective carbonic anhydrase IX inhibitors: Synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides. Bioorganic and Medicinal Chemistry, 2013, 21, 1451-1464.	1.4	55
228	The extremo-Î±-carbonic anhydrase (CA) from Sulfurihydrogenibium azorense, the fastest CA known, is highly activated by amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1087-1090.	1.0	55
229	Structural Insights on Carbonic Anhydrase Inhibitory Action, Isoform Selectivity, and Potency of Sulfonamides and Coumarins Incorporating Arylsulfonylureido Groups. Journal of Medicinal Chemistry, 2014, 57, 9152-9167.	2.9	55
230	1H-NMR studies on partially and fully reduced 2(4Fe-4S) ferredoxin from Clostridium pasteurianum. FEBS Journal, 1992, 204, 831-839.	0.2	54
231	Antimycobacterial activity of 9-sulfonylated/sulfenylated-6-mercaptopurine derivatives. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1675-1678.	1.0	54
232	Carbonic Anhydrase Activators: Gold Nanoparticles Coated with Derivatized Histamine, Histidine, and Carnosine Show Enhanced Activatory Effects on Several Mammalian Isoforms. Journal of Medicinal Chemistry, 2011, 54, 1170-1177.	2.9	54
233	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides. Bioorganic and Medicinal Chemistry, 2013, 21, 1534-1538.	1.4	54
234	Anion inhibition studies of the Î±-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1636-1638.	1.0	54

#	Article	IF	Citations
235	Monothiocarbamates Strongly Inhibit Carbonic Anhydrases in Vitro and Possess Intraocular Pressure Lowering Activity in an Animal Model of Glaucoma. Journal of Medicinal Chemistry, 2016, 59, 5857-5867.	2.9	54
236	Effects of planar and tetrahedral distortions on the ESR parameters of bis(salicylaldiminato)copper(II) complexes. Inorganic Chemistry, 1980, 19, 2198-2200.	1.9	53
237	Carbonic anhydrase inhibitors. Part 71. European Journal of Pharmaceutical Sciences, 1999, 8, 317-328.	1.9	53
238	Sulfonamide derivatives with protease inhibitory action as anticancer, anti-inflammatory and antiviral agents. Expert Opinion on Therapeutic Patents, 2002, 12, 1307-1327.	2.4	53
239	Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Cancer-associated Isozyme IX with Anions. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 403-406.	2.5	53
240	Discovery of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDsâ€“CAIs) for the Management of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2018, 61, 4961-4977.	2.9	53
241	Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: Toward agents for boron neutron capture therapy of hypoxic tumors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3302-3306.	1.0	52
242	Carbonic anhydrase activators: The first activation study of the human secretory isoform VI with amino acids and amines. Bioorganic and Medicinal Chemistry, 2007, 15, 5351-5357.	1.4	52
243	Molecular Cloning, Characterization, and Inhibition Studies of a Î²-Carbonic Anhydrase from Malassezia globosa, a Potential Antidandruff Target. Journal of Medicinal Chemistry, 2012, 55, 3513-3520.	2.9	52
244	Carbonic Anhydrase Inhibitors. Arylsulfonylureido-and Arylureido-Substituted Aromatic and Heterocyclic Sulfonamides: Towards Selective Inhibitors of Carbonic Anhydrase Isozyme I. Journal of Enzyme Inhibition and Medicinal Chemistry, 1999, 14, 343-363.	0.5	51
245	Non-peptidic Chemokine Receptors Antagonists as Emerging Anti-HIV Agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 69-76.	2.5	51
246	Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4846-4851.	1.0	51
247	Inhibition studies of a Î²-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2178-2182.	1.0	51
248	Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including Acetazolamide in human Glioblastoma. Bioorganic and Medicinal Chemistry, 2013, 21, 3949-3957.	1.4	51
249	Antifungal activity of silver and zinc complexes of sulfadrug derivatives incorporating arylsulfonylureido moieties. European Journal of Pharmaceutical Sciences, 2000, 11, 99-107.	1.9	50
250	Mono-/dihydroxybenzoic acid esters and phenol pyridinium derivatives as inhibitors of the mammalian carbonic anhydrase isoforms I, II, VII, IX, XII and XIV. Bioorganic and Medicinal Chemistry, 2013, 21, 1564-1569.	1.4	50
251	Sulfonamide inhibition studies of the Î³-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 240-244.	1.0	50
252	Carbonic Anhydrase Inhibitors: X-ray Crystallographic Structure of the Adduct of Human Isozyme II with the Perfluorobenzoyl Analogue of Methazolamide. Implications for the Drug Design of Fluorinated Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 303-308.	2.5	49

#	Article	IF	Citations
253	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2351-2356.	1.0	49
254	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2357-2361.	1.0	49
255	Carbonic anhydrase inhibitors. Inhibition of the beta-class enzyme from the methanoarchaeon Methanobacterium thermoautotrophicum (Cab) with anions. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4563-4567.	1.0	49
256	Crystal Structure of the Hydroxyquinol 1,2-Dioxygenase from Nocardioides simplex 3E, a Key Enzyme Involved in Polychlorinated Aromatics Biodegradation. Journal of Biological Chemistry, 2005, 280, 21144-21154.	1.6	49
257	Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: Kinetic and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 152-158.	1.0	49
258	Carbonic Anhydrase Inhibitors: Bioreductive Nitro-Containing Sulfonamides with Selectivity for Targeting the Tumor Associated Isoforms IX and XII. Journal of Medicinal Chemistry, 2008, 51, 3230-3237.	2.9	49
259	Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer. Current Pharmaceutical Design, 2010, 16, 3288-3299.	0.9	49
260	New chemotypes acting as isozyme-selective carbonic anhydrase inhibitors with low affinity for the offtarget cytosolic isoform II. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2182-2185.	1.0	49
261	Anion inhibition studies of the Î±-carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease. Bioorganic and Medicinal Chemistry, 2013, 21, 4472-4476.	1.4	49
262	Sulfonamide inhibition studies of the Î´-carbonic anhydrase from the diatom Thalassiosira weissflogii. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 275-279.	1.0	49
263	Anion inhibition studies of two new Î²-carbonic anhydrases from the bacterial pathogen Legionella pneumophila. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1127-1132.	1.0	49
264	Crystal Structure of 4-Chlorocatechol 1,2-Dioxygenase from the Chlorophenol-utilizing Gram-positive Rhodococcus opacus 1CP. Journal of Biological Chemistry, 2004, 279, 27646-27655.	1.6	48
265	Carbonic Anhydrase Inhibitors:Â The First On-Resin Screening of a 4-Sulfamoylphenylthiourea Library. Journal of Medicinal Chemistry, 2004, 47, 5224-5229.	2.9	48
266	Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranoseâ€“thioureido tails. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2685-2691.	1.0	48
267	Carbonic anhydrase activators: Activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4107-4112.	1.0	48
268	Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2210-2215.	1.0	48
269	Cloning, polymorphism, and inhibition of Î²-carbonic anhydrase of Helicobacter pylori. Journal of Gastroenterology, 2008, 43, 849-857.	2.3	48
270	Carbonic anhydrase inhibitors. Inhibition of transmembrane isoforms IX, XII, and XIV with less investigated anions including trithiocarbonate and dithiocarbamate. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1548-1550.	1.0	48

#	Article	IF	Citations
271	Carbonic Anhydrase Inhibitors: Synthesis of Sulfonamides Incorporating 2, 4, 6â€“Trisubstituted-Pyridinium-Ethylcarboxamido Moieties Possessing Membrane-Impermeability and in Vivo Selectivity for the Membrane-Bound (CA IV) Versus the Cytosolic (CA I and CA II) Isozymes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 381-401.	0.5	47
272	Crystal Structure of a Zinc-Activated Variant of Human Carbonic Anhydrase I, CA I Michigan 1:Â Evidence for a Second Zinc Binding Site Involving Arginine Coordination. Biochemistry, 2002, 41, 6237-6244.	1.2	47
273	Carbonic anhydrase activators: Activation of isozyme XIII with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3955-3959.	1.0	47
274	Carbonic anhydrase inhibitors: Inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamidesâ€”Solution and crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4201-4207.	1.0	47
275	Carbonic anhydrase inhibitors. Inhibition of the fungal Î²-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2642-2645.	1.0	47
276	Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms. Bioorganic and Medicinal Chemistry, 2011, 19, 3732-3738.	1.4	47
277	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5775-5780.	1.0	46
278	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxysulfamidesâ€”a new zinc-binding function in the design of inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2353-2358.	1.0	46
279	Catechol 1,2-dioxygenase from the Gram-positive Rhodococcus opacus 1CP: Quantitative structure/activity relationship and the crystal structures of native enzyme and catechols adducts. Journal of Structural Biology, 2010, 170, 548-564.	1.3	46
280	Anion inhibition studies of a Î²-carbonic anhydrase from Clostridium perfringens. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6706-6710.	1.0	46
281	A Class of 4-Sulfamoylphenyl-ï‰-aminoalkyl Ethers with Effective Carbonic Anhydrase Inhibitory Action and Antiglaucoma Effects. Journal of Medicinal Chemistry, 2014, 57, 9673-9686.	2.9	46
282	Purification and catalytic properties of two catechol 1,2-dioxygenase isozymes from benzoate-grown cells of Acinetobacter radioresistens. The Protein Journal, 2000, 19, 709-716.	1.1	45
283	Carbonic anhydrase activators: Activation of the human tumor-associated isozymes IX and XII with amino acids and amines. Bioorganic and Medicinal Chemistry, 2008, 16, 3530-3536.	1.4	45
284	2D1H NMR studies of oxidized 2(Fe4S4) ferredoxin fromClostridium pasteurianum. FEBS Letters, 1991, 289, 253-256.	1.3	44
285	Mechanism of Cyanamide Hydration Catalyzed by Carbonic Anhydrase II Suggested by Cryogenic X-ray Diffraction. Biochemistry, 2000, 39, 12391-12397.	1.2	44
286	Carbonic anhydrase inhibitors: Inhibition of human and murine mitochondrial isozymes V with anions. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2857-2861.	1.0	44
287	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. Bioorganic and Medicinal Chemistry, 2007, 15, 2298-2311.	1.4	44
288	Carbonic anhydrase activators: An activation study of the human mitochondrial isoforms VA and VB with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1336-1340.	1.0	44

#	Article	IF	Citations
289	Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3216-3221.	1.0	44
290	Sulfonamides incorporating fluorine and 1,3,5-triazine moieties are effective inhibitors of threeÎ²-class carbonic anhydrases fromMycobacterium tuberculosis. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 686-689.	2.5	44
291	Binding sites of anions in superoxide dismutase. Journal of the American Chemical Society, 1981, 103, 7779-7783.	6.6	43
292	SYNTHESIS AND CARBONIC ANHYDRASE INHIBITORY ACTIVITY OF 5-BENZOYLAMIDO- AND 5-(3-NITROBENZOYLAMIDO)- 1,3,4-THIADIAZOLE-2-SULFONAMIDE AND THEIR METAL COMPLEXES. Main Group Metal Chemistry, 1997, 20, .	0.6	43
293	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5435-5439.	1.0	43
294	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 579-584.	1.0	43
295	Sulfonamide inhibition studies of two Î²-carbonic anhydrases from the bacterial pathogen Legionella pneumophila. Bioorganic and Medicinal Chemistry, 2014, 22, 2939-2946.	1.4	43
296	Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated Î±-carbonic anhydrase from Helicobacter pylori. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2182-2188.	1.0	42
297	Restoring catalytic activity to the human carbonic anhydrase (CA) related proteins VIII, X and XI affords isoforms with high catalytic efficiency and susceptibility to anion inhibition. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 256-260.	1.0	42
298	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I and II, and extracellular isoforms IV, IX, and XII with sulfamides incorporating sugar moieties. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5086-5090.	1.0	41
299	Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XIIâ€”A new scaffold for designing isoform-selective inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6759-6763.	1.0	41
300	Proton NMR studies of the oxidized and partially reduced 2(4Fe-4S) ferredoxin from Clostridium pasteurianum. Inorganic Chemistry, 1990, 29, 1874-1880.	1.9	40
301	Transition Metal Acetylsalicylates and Their Anti-inflammatory Activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 87-91.	2.5	40
302	Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1937-1942.	1.0	40
303	Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action. Bioorganic and Medicinal Chemistry, 2015, 23, 2368-2376.	1.4	40
304	Single crystal electronic spectra and ligand field parameters of some nickel(II) amine-isothiocyanato and amine-nitrito complexes. Inorganic Chemistry, 1976, 15, 203-207.	1.9	39
305	Salicylate 1,2-Dioxygenase from Pseudaminobacter salicylatoxidans: Crystal Structure of a Peculiar Ring-cleaving Dioxygenase. Journal of Molecular Biology, 2008, 380, 856-868.	2.0	39
306	Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inhibitors of human mitochondrial isoforms VA and VB. Bioorganic and Medicinal Chemistry, 2009, 17, 4894-4899.	1.4	39

#	Article	IF	Citations
307	6-Substituted 1,2-benzoxathiine-2,2-dioxides are isoform-selective inhibitors of human carbonic anhydrases IX, XII and VA. Organic and Biomolecular Chemistry, 2015, 13, 77-80.	1.5	39
308	Carbonic Anhydrase Inhibitors. Synthesis of Topically Effective Intraocular Pressure Lowering Agents Derived from 5-(Ï‰-Amino-Alkylcarboxamido)-1,3,4-Thia-Diazole-2-Sulfonamide. Journal of Enzyme Inhibition and Medicinal Chemistry, 1999, 15, 23-46.	0.5	38
309	Hydroxyurea is a carbonic anhydrase inhibitor. Bioorganic and Medicinal Chemistry, 2003, 11, 2241-2246.	1.4	38
310	Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3757-3762.	1.0	38
311	Carbonic Anhydrase Inhibitors:â€‰ Synthesis and Topical Intraocular Pressure Lowering Effects of Fluorine-Containing Inhibitors Devoid of Enhanced Reactivity. Journal of Medicinal Chemistry, 2004, 47, 2796-2804.	2.9	38
312	Carbonic anhydrase inhibitors: Binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1726-1731.	1.0	38
313	Inhibition of the R1 fragment of the cadmium-containing Î¶-class carbonic anhydrase from the diatom Thalassiosira weissflogii with anions. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4745-4748.	1.0	38
314	Kinetic and anion inhibition studies of a Î²-carbonic anhydrase (FbiCA 1) from the C4 plant Flaveria bidentis. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1626-1630.	1.0	38
315	Plasmonic Particles that Hit Hypoxic Cells. Advanced Functional Materials, 2015, 25, 316-323.	7.8	38
316	Sulfenamido-Sulfonamides as Inhibitors of Carbonic Anhydrase Isozymes I, II And IV. Journal of Enzyme Inhibition and Medicinal Chemistry, 1997, 12, 175-190.	0.5	37
317	Molecular modeling study for the binding of zonisamide and topiramate to the human mitochondrial carbonic anhydrase isoform VA. Bioorganic and Medicinal Chemistry, 2007, 15, 4152-4158.	1.4	37
318	Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: Kinetic and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4866-4872.	1.0	37
319	Carbonic anhydrase inhibitors: Thioxolone versus sulfonamides for obtaining isozyme-selective inhibitors?. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3938-3941.	1.0	37
320	Carbonic anhydrase inhibitors: Copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 836-841.	1.0	37
321	Carbonic anhydrase inhibitors: synthesis of N -morpholyl-thiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1117-1120.	1.0	36
322	Protease Inhibitors:Â Synthesis of a Series of Bacterial Collagenase Inhibitors of the Sulfonyl Amino Acyl Hydroxamate Type. Journal of Medicinal Chemistry, 2001, 44, 2253-2258.	2.9	36
323	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a bis-sulfonamideâ€”two heads are better than one?. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2759-2763.	1.0	36
324	Synthesis of Biologically Active Co(II), Cu(II), Ni(II) and Zn(II) Complexes of Symmetrically 1,1â€²â€Disubstituted Ferroceneâ€Derived Compounds. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2003, 33, 241-257.	1.8	36

#	Article	IF	Citations
325	Benzolamide is not a Membrane-impermeant Carbonic Anhydrase Inhibitor. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 269-273.	2.5	36
326	Crystal Structure of 3-Chlorocatechol 1,2-dioxygenase Key Enzyme of a New Modified Ortho-pathway from the Gram-positive Rhodococcus opacus 1CP Grown on 2-chlorophenol. Journal of Molecular Biology, 2006, 360, 788-799.	2.0	36
327	Carbonic anhydrase activators: Activation of the archaeal Î²-class (Cab) and Î³-class (Cam) carbonic anhydrases with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6194-6198.	1.0	36
328	Carbonic anhydrase inhibitors. Cloning, characterization and inhibition studies of the cytosolic isozyme III with anions. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 70-76.	2.5	36
329	Î±-Carbonic Anhydrases Possess Thioesterase Activity. ACS Medicinal Chemistry Letters, 2015, 6, 292-295.	1.3	36
330	Inhibition of Carbonic Anhydrase IX: A New Strategy Against Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 693-702.	0.9	36
331	X-ray Absorption Studies on Catechol 2,3-Dioxygenase from Pseudomonas putida MT2. Biochemistry, 1994, 33, 10777-10784.	1.2	35
332	Characterization of an intradiol dioxygenase involved in the biodegradation of the chlorophenoxy herbicides 2,4-D and 2,4,5-T. FEBS Letters, 1997, 407, 69-72.	1.3	35
333	Novel carbonic anhydrase isozymes I, II and IV activators incorporating sulfonyl-histamino moieties. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2043-2048.	1.0	35
334	3D QSAR Selectivity Analyses of Carbonic Anhydrase Inhibitors:â€‰ Insights for the Design of Isozyme Selective Inhibitors. Journal of Chemical Information and Modeling, 2006, 46, 2737-2760.	2.5	35
335	N-Hydroxyureaâ€”A versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4316-4320.	1.0	35
336	Carbonic anhydrase inhibitors. Inhibition of transmembrane isozymes XII (cancer-associated) and XIV with anions. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1532-1537.	1.0	35
337	Carbonic anhydrase inhibitors: The X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2669-2674.	1.0	35
338	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1855-1857.	1.0	35
339	Tricyclic Sulfonamides Incorporating Benzothiopyrano[4,3-c]pyrazole and Pyridothiopyrano[4,3-c]pyrazole Effectively Inhibit Î±- and Î²-Carbonic Anhydrase: X-ray Crystallography and Solution Investigations on 15 Isoforms. Journal of Medicinal Chemistry, 2012, 55, 9619-9629.	2.9	35
340	Inhibition of Î±-class cytosolic human carbonic anhydrases I, II, IX and XII, and Î²-class fungal enzymes by carboxylic acids and their derivatives: New isoform-I selective nanomolar inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5801-5806.	1.0	35
341	New Advances in HIV Entry Inhibitors Development. Current Drug Targets Infectious Disorders, 2004, 4, 339-355.	2.1	35
342	Carbonic anhydrase activators. European Journal of Pharmaceutical Sciences, 2000, 10, 29-41.	1.9	34

#	Article	IF	Citations
343	Antibacterial Cobalt(II), Nickel(II) and Zinc(II) Complexes of Nicotinic Acid-derived Schiff-bases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 101-106.	2.5	34
344	Carbonic anhydrase inhibitors: Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4872-4876.	1.0	34
345	Carbonic anhydrase inhibitors. Phenacetyl-, pyridylacetyl- and thienylacetyl-substituted aromatic sulfonamides act as potent and selective isoform VII inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3170-3173.	1.0	34
346	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: The Î²-class (PgiCAb) versus the Î³-class (PgiCA) enzymes. Bioorganic and Medicinal Chemistry, 2014, 22, 4537-4543.	1.4	34
347	Carbonic Anhydrase Inhibitors: Synthesis of Water Soluble Sulfonamides Incorporating a 4-sulfamoylphenylmethylthiourea Scaffold, with Potent Intraocular Pressure Lowering Properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 333-343.	2.5	33
348	Cysteine-modifying agents: a possible approach for effective anticancer and antiviral drugs.. Environmental Health Perspectives, 2002, 110, 801-806.	2.8	33
349	Protein tyrosine kinase inhibitors as anticancer agents. Expert Opinion on Therapeutic Patents, 2004, 14, 35-53.	2.4	33
350	Carbonic anhydrase inhibitors. Inhibition studies of the human secretory isoform VI with anions. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1037-1042.	1.0	33
351	External pH influences the transcriptional profile of the carbonic anhydrase, CAH-4b in Caenorhabditis elegans. Molecular and Biochemical Parasitology, 2008, 161, 140-149.	0.5	33
352	Carbonic anhydrase inhibitors. Inhibition of the Î²-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2521-2526.	1.0	33
353	Sulfonamide inhibition studies of the Î³-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune. Bioorganic and Medicinal Chemistry, 2015, 23, 1728-1734.	1.4	33
354	Ligand field interpretation of high-spin trigonal-bipyramidal cobalt(II) complexes. Inorganic Chemistry, 1975, 14, 812-815.	1.9	32
355	Carbonic Anhydrase Inhibitors. Schiff Bases of some Aromatic Sulfonamides and Their Metal Complexes: Towards More Selective Inhibitors of Carbonic Anhydrase Isozyme IV. Journal of Enzyme Inhibition and Medicinal Chemistry, 1999, 14, 407-423.	0.5	32
356	Carbonic anhydrase activators â€“ Part 21. Novel activators of isozymes I, II and IV incorporating carboxamido and ureido histamine moieties. European Journal of Medicinal Chemistry, 2000, 35, 31-39.	2.6	32
357	Carbonic Anhydrase Inhibitors: Inhibition of Isozymes I, II and IV by Sulfamide and Sulfamic Acid Derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 443-453.	0.5	32
358	Protease Inhibitors:Â Synthesis and QSAR Study of Novel Classes of Nonbasic Thrombin Inhibitors Incorporating Sulfonylguanidine andO-Methylsulfonylisourea Moieties at P1. Journal of Medicinal Chemistry, 2000, 43, 1793-1806.	2.9	32
359	Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of 5-amino-1,3,4-thiadiazole-2-sulfonamide and 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide to human isoform II. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6204-6208.	1.0	32
360	Laccase isoforms with unusual properties from the basidiomyceteSteccherinum ochraceumstrain 1833. Journal of Applied Microbiology, 2008, 105, 2065-2075.	1.4	32

#	Article	IF	Citations
361	Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 715-719.	1.0	32
362	Furazan and furoxan sulfonamides are strong Î±-carbonic anhydrase inhibitors and potential antiglaucoma agents. Bioorganic and Medicinal Chemistry, 2014, 22, 3913-3921.	1.4	32
363	Evidence of exchangeable protons in the donor groups of the acidic form of cobalt bovine carbonic anhydrase B. Biochemical and Biophysical Research Communications, 1977, 78, 158-160.	1.0	31
364	Interaction of cobalt(II) bovine carbonic anhydrase with aniline, benzoate, and anthranilate. Journal of the American Chemical Society, 1977, 99, 581-584.	6.6	31
365	Superoxide dismutase-thiocyanate: a study of the binding sites of anions on copper(II) in superoxide dismutase. Journal of the American Chemical Society, 1980, 102, 7349-7353.	6.6	31
366	Sulfonylamido derivatives of aminoglutethimide and their copper(II) complexes: a novel class of antifungal compounds. European Journal of Medicinal Chemistry, 1997, 32, 901-910.	2.6	31
367	Carbonic Anhydrase Inhibitors. Water-Soluble, Topically Effective Intraocular Pressure Lowering Agents Derived from Isonicotinic Acid and Aromatic/Heterocyclic Sulfonamides: Is the Tail More Important than the Ring?. Journal of Enzyme Inhibition and Medicinal Chemistry, 1999, 14, 457-474.	0.5	31
368	Protease inhibitors: Synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2667-2672.	1.0	31
369	Carbonic anhydrase inhibitors: Topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2867-2873.	1.0	31
370	Therapeutic applications of sulfamates. Expert Opinion on Therapeutic Patents, 2004, 14, 1273-1308.	2.4	31
371	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbonate. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 567-571.	1.0	31
372	Carbonic anhydrase inhibitors: Inhibition studies of a coral secretory isoform with inorganic anions. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 650-653.	1.0	31
373	An inhibitor-like binding mode of a carbonic anhydrase activator within the active site of isoform II. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2764-2768.	1.0	31
374	Metalloenzyme inhibitors for the treatment of Gram-negative bacterial infections: a patent review (2009 â€“ 2012). Expert Opinion on Therapeutic Patents, 2013, 23, 777-788.	2.4	31
375	Interaction of cobalt-bovine carbonic anhydrase with the acetate ion. Biochimica Et Biophysica Acta - Biomembranes, 1976, 452, 239-244.	1.4	30
376	The acid-base equilibria of carbonic anhydrase. Inorganica Chimica Acta, 1980, 46, 85-89.	1.2	30
377	A ternary complex of carbonic anhydrase: X-ray crystallographic structure of the adduct of human carbonic anhydrase II with the activator phenylalanine and the inhibitor azide. Inorganica Chimica Acta, 1998, 275-276, 295-300.	1.2	30
378	4-Toluenesulfonylureido derivatives of amines, amino acids and dipeptides: a novel class of potential antitumor agents. European Journal of Pharmaceutical Sciences, 2000, 11, 325-332.	1.9	30

#	Article	IF	Citations
379	Carbonic Anhydrase Activators: Synthesis of High Affinity Isozymes I, II and IV Activators, Derivatives of 4-(4-Tosylureido-Amino Acyl)Ethyl-1H-Imidazole (Histamine Derivatives). Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 139-161.	0.5	30
380	Carbonic anhydrase activators: Activation of the human cytosolic isozyme III and membrane-associated isoform IV with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4303-4307.	1.0	30
381	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorganic and Medicinal Chemistry, 2009, 17, 5054-5058.	1.4	30
382	1H NOE studies of oxidized high potential iron sulfur protein II from Ectothiorhodospira halophila. Inorganica Chimica Acta, 1991, 180, 171-175.	1.2	29
383	Carbonic Anhydrase Inhibitors: Ureido and Thioureido Derivatives of Aromatic Sulfonamides Possessing Increased Affinities for Isozyme I. A Novel Route To 2,5-Disubstituted-L,3,4-Thiadiazoles Via Thioureas, and Their Interaction with Isozymes I, II and IV. Journal of Enzyme Inhibition and Medicinal Chemistry, 1998, 13, 103-123.	0.5	29
384	Protease inhibitors: synthesis of Clostridium histolyticum collagenase inhibitors incorporating sulfonyl-l-alanine hydroxamate moieties. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 499-502.	1.0	29
385	Protease inhibitors â€“ Part 5. Alkyl/arylsulfonyl- and arylsulfonylureido-/arylureido- glycine hydroxamate inhibitors of Clostridium histolyticum collagenase. European Journal of Medicinal Chemistry, 2000, 35, 299-307.	2.6	29
386	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5781-5786.	1.0	29
387	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1149-1154.	1.0	29
388	Carbonic anhydrase inhibitors: Inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1538-1543.	1.0	29
389	Carbonic anhydrase inhibitors: Inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides. Bioorganic and Medicinal Chemistry, 2008, 16, 3933-3940.	1.4	29
390	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isoforms I and II and transmembrane, tumor-associated isoforms IX and XII with boronic acids. Bioorganic and Medicinal Chemistry, 2009, 17, 3649-3652.	1.4	29
391	Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 Î²-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesulfonamides. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4929-4932.	1.0	29
392	Pyridinium derivatives of histamine are potent activators of cytosolic carbonic anhydrase isoforms I, II and VII. Organic and Biomolecular Chemistry, 2011, 9, 2790.	1.5	29
393	Differential decolorization of textile dyes in mixtures and the joint effect of laccase and cellobiose dehydrogenase activities present in extracellular extracts from Funalia trogii. Enzyme and Microbial Technology, 2011, 49, 465-471.	1.6	29
394	Crystal structures of salicylate 1,2-dioxygenase-substrates adducts: A step towards the comprehension of the structural basis for substrate selection in class III ring cleaving dioxygenases. Journal of Structural Biology, 2012, 177, 431-438.	1.3	29
395	Inhibition of beta-carbonic anhydrases from the bacterial pathogen Brucella suis with inorganic anions. Journal of Inorganic Biochemistry, 2012, 110, 36-39.	1.5	29
396	Dipotassium-trioxohydroxytetrafluorotriborate, K₂[B₃O₃F₄OH], is a potent inhibitor of human carbonic anhydrases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 341-344.	2.5	29

#	Article	IF	Citations
397	Binding affinity of bicarboxylate ions for cobalt(II) bovine carbonic anhydrase. Bioinorganic Chemistry, 1978, 9, 93-100.	1.2	28
398	Carbonic anhydrase activators. Part 17. Synthesis and activation study of a series of 1-(1,2,4-triazole-(1H)-3-yl)-2,4,6-trisubstituted-pyridinium salts against isozymes I, II and IV. European Journal of Medicinal Chemistry, 1997, 32, 911-918.	2.6	28
399	Carbonic Anhydrase Inhibitors: Inhibition of Isozymes I, II and IV withN-Hydroxysulfonamides - A Novel Class of Intraocular Pressure Lowering Agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 1998, 13, 267-284.	0.5	28
400	Carbonic anhydrase activators: amino acyl/dipeptidyl histamine derivatives bind with high affinity to isozymes I, II and IV and act as efficient activators. Bioorganic and Medicinal Chemistry, 1999, 7, 2915-2923.	1.4	28
401	Protease inhibitors. Part 8: synthesis of potent Clostridium histolyticum collagenase inhibitors incorporating sulfonylated l -alanine hydroxamate moieties. Bioorganic and Medicinal Chemistry, 2000, 8, 637-645.	1.4	28
402	Antifungal Activity of Ag(I) and Zn(Ii) Complexes of Aminobenzolamide (5-Sulfanilylamido-1,3,4-Thiadiazole-2-Sulfonamide) Derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 517-531.	0.5	28
403	Activation of carbonic anhydrase isozymes. , 2000, , 197-219.		28
404	Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating arylsulfonylureido and 5-dibenzo-suberenyl/suberyl moieties. Bioorganic and Medicinal Chemistry, 2003, 11, 2227-2239.	1.4	28
405	Carbonic anhydrase inhibitors. Inhibition of the zinc and cobalt Î³-class enzyme from the archaeon Methanosarcina thermophila with anions. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3327-3331.	1.0	28
406	Carbonic anhydrase inhibitors: Design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3821-3827.	1.0	28
407	Carbonic Anhydrase Inhibitors: Design of Membraneâ€Impermeant Copper(II) Complexes of DTPAâ€, DOTAâ€, and TETAâ€Tailed Sulfonamides Targeting the Tumorâ€Associated Transmembrane Isoform IX. ChemMedChem, 2008, 3, 1780-1788.	1.6	28
408	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 710-714.	1.0	28
409	Reaction intermediates and redox state changes in a blue laccase from Steccherinum ochraceum observed by crystallographic high/low X-ray dose experiments. Journal of Inorganic Biochemistry, 2012, 111, 203-209.	1.5	28
410	Anion inhibition study of the Î²-class carbonic anhydrase (PgiCAb) from the oral pathogen Porphyromonas gingivalis. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4402-4406.	1.0	28
411	Sulfonamide inhibition studies of the Î³-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3550-3555.	1.0	28
412	Aliphatic and aromatic inhibitors binding to the active site of catechol 2,3-dioxygenase fromPseudomonas putidamt-2. FEBS Letters, 1994, 343, 56-60.	1.3	27
413	Carbonic Anhydrase Inhibitors. Part 461 Inhibition of Carbonic Anhydrase Isozymes I, II and IV With Trifluoromethylsulfonamide Derivatives and Their Zinc(II) and Copper(II) Complexes. Metal-Based Drugs, 1997, 4, 27-34.	3.8	27
414	Protease inhibitors. Part 7. European Journal of Pharmaceutical Sciences, 2000, 10, 67-76.	1.9	27

#	Article	IF	Citations
415	Agents that target cysteine residues of biomolecules and their therapeutic potential. Expert Opinion on Therapeutic Patents, 2001, 11, 765-787.	2.4	27
416	Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2765-2768.	1.0	27
417	Carbonic anhydrase inhibitors. The Î²-carbonic anhydrases from the fungal pathogens Cryptococcus neoformans and Candida albicans are strongly inhibited by substituted-phenyl-1H-indole-5-sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2508-2511.	1.0	27
418	Proteinâ€“Protein Interactions: Inhibition of Mammalian Carbonic Anhydrases Iâ€“XV by the Murine Inhibitor of Carbonic Anhydrase and Other Members of the Transferrin Family. Journal of Medicinal Chemistry, 2012, 55, 5529-5535.	2.9	27
419	Development and ex vivo evaluation of 5-aminolevulinic acid-loaded niosomal formulations for topical photodynamic therapy. International Journal of Pharmaceutics, 2015, 494, 258-263.	2.6	27
420	Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5769-5773.	1.0	26
421	Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4862-4866.	1.0	26
422	Carbonic anhydrase inhibitors: Inhibition of the cytosolic human isozyme VII with anions. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3139-3143.	1.0	26
423	Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5096-5100.	1.0	26
424	Role of surfactants in optimizing fluorene assimilation and intermediate formation by Rhodococcus rhodochrous VKM B-2469. Bioresource Technology, 2009, 100, 839-844.	4.8	26
425	Inhibition of Î²-carbonic anhydrases with ureido-substituted benzenesulfonamides. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 102-105.	1.0	26
426	Cloning, characterization and anion inhibition studies of a new Î³-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis. Bioorganic and Medicinal Chemistry, 2015, 23, 4405-4409.	1.4	26
427	Staticâ€“dynamic distortions of the tris(1,2-diaminoethane)copper(II) cation [Cu(en)3]2+. Crystal structures of the salts [Cu(en)3][SO4] at 120 K and of [Cu(en)3]Cl2Â·0.75 en at 298 K. Journal of the Chemical Society Dalton Transactions, 1979, , 1409-1414.	1.1	25
428	Carbonic Anhydrase Inhibitors: Synthesis of Schiff Bases of Hydroxybenzaldehydes with Aromatic Sulfonamides and Their Reactions with Arylsulfonyl Isocyanates. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 533-546.	0.5	25
429	Therapeutic applications of serine protease inhibitors. Expert Opinion on Therapeutic Patents, 2002, 12, 1181-1214.	2.4	25
430	Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1551-1557.	1.0	25
431	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1683-1686.	1.0	25
432	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2359-2364.	1.0	25

#	Article	IF	Citations
433	Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 499-505.	2.5	25
434	Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3063-3066.	1.0	25
435	The salicylate 1,2â€dioxygenase as a model for a conventional gentisate 1,2â€dioxygenase: crystal structures of the G106A mutant and its adducts with gentisate and salicylate. FEBS Journal, 2013, 280, 1643-1652.	2.2	25
436	Anion inhibition study of the Î²-carbonic anhydrase (CahB1) from the cyanobacterium Coleofasciculus chthonoplastes (ex-Microcoleus chthonoplastes). Bioorganic and Medicinal Chemistry, 2014, 22, 1667-1671.	1.4	25
437	Complexes With Biologically Active Ligands. Part 101 Inhibition of Carbonic Anhydrase Isozymes I and II With Metal Complexes of Imidazo[2,1â^'b]-1,3,4-Thiadiazole-2-Sulfonamide. Metal-Based Drugs, 1997, 4, 19-26.	3.8	24
438	Carbonic Anhydrase Inhibitors: Inhibition of Isozymes I, II And IV with Heterocyclic Mercaptans, Sulfenamides, Sulfonamides and their Metal Complexes. Journal of Enzyme Inhibition and Medicinal Chemistry, 1998, 13, 177-194.	0.5	24
439	Small molecule antagonists of chemokine receptors as emerging anti-HIV agents. Expert Opinion on Therapeutic Patents, 2001, 11, 1245-1252.	2.4	24
440	Transport characteristics of L-carnosine and the anticancer derivative 4-toluenesulfonylureido-carnosine in a human epithelial cell line. Pharmaceutical Research, 2002, 19, 1337-1344.	1.7	24
441	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5763-5767.	1.0	24
442	Carbonic anhydrase inhibitors: Inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 5192-5196.	1.0	24
443	Carbonic anhydrase inhibitors: 2-Substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes VA and VB over the cytosolic and membrane-associated carbonic anhydrases I, II and IV. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6332-6335.	1.0	24
444	Cloning, Expression, Post-Translational Modifications and Inhibition Studies on the Latest Mammalian Carbonic Anhydrase Isoform, CA XV. Journal of Medicinal Chemistry, 2009, 52, 646-654.	2.9	24
445	Biodegradation of 2-naphthalensulfonic acid polymers by white-rot fungi: Scale-up into non-sterile packed bed bioreactors. Chemosphere, 2016, 164, 120-127.	4.2	24
446	Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Cancer-associated Isozyme IX with Lipophilic Sulfonamides. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 333-338.	2.5	23
447	Carbonic anhydrase inhibitors: Synthesis and inhibition studies against mammalian isoforms Iâ€“XV with a series of 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides. Bioorganic and Medicinal Chemistry, 2008, 16, 9113-9120.	1.4	23
448	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II and IX with some 1,3,4-oxadiazole- and 1,2,4-triazole-thiols. Journal of Enzyme Inhibition and Medicinal Chemistry, 2008, 23, 101-107.	2.5	23
449	Carbonic anhydrase activators: Activation of human isozymes I, II and IX with phenylsulfonylhydrazido l-histidine derivatives. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2440-2443.	1.0	23
450	Carbonic anhydrase I and II activation with mono- and dihalogenated histamine derivatives. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4884-4887.	1.0	23

#	Article	IF	Citations
451	Inhibition studies of new ureido-substituted sulfonamides incorporating a GABA moiety against human carbonic anhydrase isoforms Iâ€“XIV. Bioorganic and Medicinal Chemistry, 2014, 22, 6768-6775.	1.4	23
452	Spectroscopic investigation of copper(II) bovine carbonic anhydrase and its inhibitor derivatives. Journal of the Chemical Society Dalton Transactions, 1978, , 1269.	1.1	22
453	Advances in the NMR investigation of paramagnetic molecules in solution. Coordination Chemistry Reviews, 1992, 120, 1-28.	9.5	22
454	Biophysical investigation of bacterial aromatic extradiol dioxygenases involved in biodegradation processes. Coordination Chemistry Reviews, 1995, 144, 321-345.	9.5	22
455	Metal Binding Functions in the Design of Carbonic Anhydrase Inhibitors. Current Topics in Medicinal Chemistry, 2007, 7, 835-848.	1.0	22
456	Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: Kinetic and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 999-1005.	1.0	22
457	Serendipitous fragment-based drug discovery: ketogenic diet metabolites and statins effectively inhibit several carbonic anhydrases. Chemical Communications, 2012, 48, 3551.	2.2	22
458	Carbonic anhydrase inhibitors: Inhibition of the human transmembrane isozyme XIV with a library of aromatic/heterocyclic sulfonamides. Bioorganic and Medicinal Chemistry, 2005, 13, 6089-6093.	1.4	21
459	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: Structureâ€“activity relationship and pharmacological evaluation. European Journal of Medicinal Chemistry, 2008, 43, 2853-2860.	2.6	21
460	Carbonic anhydrase activators: Activation of the Î²-carbonic anhydrase Nce103 from the yeast Saccharomyces cerevisiae with amines and amino acids. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1662-1665.	1.0	21
461	Synthesis of sulfonamides with effective inhibitory action against Porphyromonas gingivalis Î³-carbonic anhydrase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4006-4010.	1.0	21
462	A new class of inhibitors capable of binding both the acidic and alkaline forms of carbonic anhydrase. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1981, 668, 16-26.	1.7	20
463	XAS characterization of the active sites of novel intradiol ring-cleaving dioxygenases: hydroxyquinol and chlorocatechol dioxygenases. FEBS Letters, 1998, 433, 58-62.	1.3	20
464	Carbonic Anhydrase Inhibitors: Metal Complexes of a Sulfanilamide Derived Schiff base and their Interaction with Isozymes I, II and IV. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 499-505.	0.5	20
465	Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides. Journal of Enzyme Inhibition and Medicinal Chemistry, 2005, 20, 211-217.	2.5	20
466	Inhibitors of HIV-1 protease: 10 years after. Expert Opinion on Therapeutic Patents, 2006, 16, 1067-1091.	2.4	20
467	Design, solid-phase synthesis, and biological evaluation of novel 1,5-diarylpyrrole-3-carboxamides as carbonic anhydrase IX inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 7392-7401.	1.4	20
468	Inhibition of tumor-associated human carbonic anhydrase isozymes IX and XII by a new class of substituted-phenylacetamido aromatic sulfonamides. Bioorganic and Medicinal Chemistry, 2013, 21, 5228-5232.	1.4	20

#	Article	IF	Citations
469	Structural effect of phenyl ring compared to thiadiazole based adamantyl-sulfonamides on carbonic anhydrase inhibition. Bioorganic and Medicinal Chemistry, 2013, 21, 2314-2318.	1.4	20
470	Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators. Bioorganic and Medicinal Chemistry, 2014, 22, 4752-4758.	1.4	20
471	Fluorescent sulfonamide carbonic anhydrase inhibitors incorporating 1,2,3-triazole moieties: Kinetic and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry, 2016, 24, 104-112.	1.4	20
472	Selective interaction of ferricyanide with cluster I of Clostridium pasteurianum 2[Fe4 S4] ferredoxin. FEBS Letters, 1993, 332, 268-272.	1.3	19
473	Complexes With Biologically Active Ligands. Part 61 Ni(II) Coordination Compounds of Hydrazine and Heterocyclic Sulfonamides as Inhibitors of the Zinc Enzyme Carbonic Anhydrase. Metal-Based Drugs, 1996, 3, 143-148.	3.8	19
474	Functionalized Derivatives of Benzocrown Ethers, II. Supramolecular Complexes of <scp>L</scp>â€Amino Acids as Efficient Activators of the Zinc Enzyme Carbonic Anhydrase. Liebigs Annalen, 1997, 1997, 1853-1859.	0.8	19
475	Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides. Journal of Enzyme Inhibition and Medicinal Chemistry, 2006, 21, 563-568.	2.5	19
476	Carbonic anhydrase activators: Activation of the Î²-carbonic anhydrases from the pathogenic fungi Candida albicans and Cryptococcus neoformans with amines and amino acids. Bioorganic and Medicinal Chemistry, 2010, 18, 1034-1037.	1.4	19
477	Carbonic anhydrase activators: Activation of the Î²-carbonic anhydrase from the pathogenic yeast Candida glabrata with amines and amino acids. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1701-1704.	1.0	19
478	Carbonic Anhydrase Interaction With Lipothioars Enites: A Novel Class of Isozymes I and II Inhibitors. Metal-Based Drugs, 1996, 3, 263-268.	3.8	18
479	Quantitative structure/activity relationship for the rate of conversion of C4-substituted catechols by catechol-1,2-dioxygenase from Pseudomonas putida (arvilla) C1. FEBS Journal, 1998, 257, 92-100.	0.2	18
480	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1909-1913.	1.0	18
481	Evaluation of an FIA Operated Amperometric Bacterial Biosensor, Based on Pseudomonas Putida F1 for the Detection of Benzene, Toluene, Ethylbenzene, and Xylenes (BTEX). Analytical Letters, 2005, 38, 1531-1547.	1.0	18
482	Carbonic anhydrase inhibitors: Transepithelial transport of thioureido sulfonamide inhibitors of the cancer-associated isozyme IX is dependent on efflux transporters. Bioorganic and Medicinal Chemistry, 2006, 14, 2418-2427.	1.4	18
483	Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the cytosolic isoforms I and II. Bioorganic and Medicinal Chemistry, 2009, 17, 7093-7099.	1.4	18
484	A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode Î±-carbonic anhydrases. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1371-1375.	1.0	18
485	3-Phenyl-1H-Indole-5-Sulfonamides: Structure-Based Drug Design of a Promising Class of Carbonic Anhydrase Inhibitors. Current Pharmaceutical Design, 2010, 16, 3317-3326.	0.9	18
486	Inhibition of human carbonic anhydrase isoforms Iâ€“XIV with sulfonamides incorporating fluorine and 1,3,5-triazine moieties. Bioorganic and Medicinal Chemistry, 2013, 21, 6929-6936.	1.4	18

#	Article	IF	Citations
487	Anion inhibition studies of two Î±-carbonic anhydrases from Lotus japonicus, LjCAA1 and LjCAA2. Journal of Inorganic Biochemistry, 2014, 136, 67-72.	1.5	18
488	Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 466-471.	2.5	18
489	Single crystal ESR study of the Cu(en)3SO4 complex. Inorganica Chimica Acta, 1974, 11, L17-L19.	1.2	17
490	The antifungal activity of sulfonylamido derivatives of 2-aminophenoxathiin and related compounds. European Journal of Medicinal Chemistry, 1998, 33, 821-830.	2.6	17
491	Carbonic Anhydrase Inhibitors:N-Cyanosulfonamides, a new Class of High Affinity Isozyme II and IV Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 1999, 14, 289-306.	0.5	17
492	Carbonic Anhydrase Inhibitors. Part 91. Metal Complexes of Heterocyclic Sulfonamides as Potential Pharmacological Agents in the Treatment of Gastric Acid Secretion Imbalances. Metal-Based Drugs, 2000, 7, 57-62.	3.8	17
493	Efficient polycyclic aromatic hydrocarbons dihydroxylation in direct micellar systems. Biotechnology and Bioengineering, 2001, 74, 240-248.	1.7	17
494	Protease Inhibitors: Synthesis of Bacterial Collagenase and Matrix Metalloproteinase Inhibitors Incorporating Succinyl Hydroxamate and Iminodiacetic Acid Hydroxamate Moieties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 233-242.	2.5	17
495	Carbonic anhydrase inhibitors: The inhibition profiles of the human mitochondrial isoforms VA and VB with anions are very different. Bioorganic and Medicinal Chemistry, 2007, 15, 6742-6747.	1.4	17
496	Benzenesulfonamides incorporating bulky aromatic/heterocyclic tails with potent carbonic anhydrase inhibitory activity. Bioorganic and Medicinal Chemistry, 2015, 23, 7751-7764.	1.4	17
497	Dithiocarbamates with potent inhibitory activity against theSaccharomyces cerevisiaeÎ²-carbonic anhydrase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 132-136.	2.5	17
498	Sulphonamide inhibition studies of the Î²-carbonic anhydrase from the bacterial pathogenClostridium perfringens. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 31-36.	2.5	17
499	Polymetallic macromolecules are potential contrast agents of improved efficiency. Magnetic Resonance in Medicine, 1994, 31, 58-60.	1.9	16
500	Protease inhibitors. European Journal of Pharmaceutical Sciences, 2000, 11, 69-79.	1.9	16
501	Antimycobacterial Activity of 3,4-dichlorophenyl-ureas, N,N-diphenyl-ureas and Related Derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 425-432.	0.5	16
502	Cyclodextrin Complexes of Sulfonamide Carbonic Anhydrase IOnhibitors As Longâ€lasting Topically Acting Antiglaucoma Agents. Journal of Pharmaceutical Sciences, 2002, 91, 2211-2219.	1.6	16
503	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5703-5707.	1.0	16
504	Carbonic anhydrase inhibitors: Design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3475-3480.	1.0	16

#	Article	IF	Citations
505	Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2931-2934.	1.0	16
506	Carbonic anhydrase inhibitors. The nematode Î±-carbonic anhydrase of Caenorhabditis elegans CAH-4b is highly inhibited by 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides. Bioorganic and Medicinal Chemistry, 2009, 17, 3212-3215.	1.4	16
507	Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes. Current Pharmaceutical Design, 2012, 18, 1407-1413.	0.9	16
508	The unusual behavior of the inhibitor S(+)(1-amino-2-phenylethyl)phosphonic acid towards carboxypeptidase A. Journal of Inorganic Biochemistry, 1990, 40, 227-235.	1.5	15
509	Carbonic anhydrase inhibitors. Part 79. European Journal of Pharmaceutical Sciences, 1999, 9, 185-199.	1.9	15
510	Carbonic Anhydrase Activators: Synthesis of High Affinity Isozymes I, II and IV Activators, Derivatives of 4-(Arylsulfonylureido-Amino Acyl)Ethyl-1H-Imidazole. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 471-486.	0.5	15
511	Protease Inhibitors: Synthesis of L-Alanine Hydroxamate Sulfonylated Derivatives as Inhibitors ofClostridium HistolyticumCollagenase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 111-128.	0.5	15
512	Carbonic anhydrase inhibitors: The X-ray crystal structure of the adduct of N-hydroxysulfamide with isozyme II explains why this new zinc binding function is effective in the design of potent inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2795-2801.	1.0	15
513	Combined action of a bacterial monooxygenase and a fungal laccase for the biodegradation of mono- and poly-aromatic hydrocarbons. Bioresource Technology, 2008, 99, 8353-8359.	4.8	15
514	Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents. Anti-Infective Agents in Medicinal Chemistry, 2008, 7, 169-179.	0.6	15
515	Carbonic anhydrase inhibitors: The membrane-associated isoform XV is highly inhibited by inorganic anions. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1155-1158.	1.0	15
516	Effect of carbon source on the degradation of 2-naphthalenesulfonic acid polymers mixture by Pleurotus ostreatus in petrochemical wastewater. Process Biochemistry, 2014, 49, 2272-2278.	1.8	15
517	Kinetic and X-ray crystallographic investigations of substituted 2-thio-6-oxo-1,6-dihydropyrimidineâ€“benzenesulfonamides acting as carbonic anhydrase inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 3643-3648.	1.4	15
518	Synthesis and inhibition potency of novel ureido benzenesulfonamides incorporating GABA as tumor-associated carbonic anhydrase IX and XII inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 205-211.	2.5	15
519	The metal-binding properties of ovotransferrin. An investigation of cobalt(II) derivatives.. Journal of Biological Chemistry, 1986, 261, 1139-1146.	1.6	15
520	Proton magnetic resonance spectra of six-coordinate iron(II), cobalt(II), and nickel(II) complexes with pyridine-n-oxide and benzamide. Inorganica Chimica Acta, 1972, 6, 185-187.	1.2	14
521	Carbon-13 longitudinal relaxation times of acetate ion in the presence of metal-substituted bovine carbonic anhydrases. Journal of the Chemical Society Dalton Transactions, 1977, , 1962.	1.1	14
522	Paramagnetic Metal Centers in Proteins Investigated through Heterocorrelated NMR Spectroscopy. Journal of Magnetic Resonance Series B, 1994, 104, 95-98.	1.6	14

#	Article	IF	Citations
523	Carbonic anhydrase inhibitors â€“ part 70. Synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering agents derived from nicotinic acid and aromatic/heterocyclic sulfonamides. European Journal of Medicinal Chemistry, 1999, 34, 799-808.	2.6	14
524	Carbonic Anhydrase Inhibitors With Strong Topical Antiglaucoma Properties Incorporating a 4-(2-amino-pyrimidin-4-yl-amino)-benzenesulfonamide Scaffold. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 9-18.	2.5	14
525	Design of Weakly Basic Thrombin Inhibitors Incorporating Novel P1 Binding Functions:Â Molecular and X-ray Crystallographic Studiesâ€. Biochemistry, 2003, 42, 9013-9021.	1.2	14
526	Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2975-2979.	1.0	14
527	1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads. Bioorganic and Medicinal Chemistry, 2017, 25, 4560-4565.	1.4	14
528	Single crystal polarized electronic spectra of a five-coordinate macrocyclic complex of nickel(II). Inorganica Chimica Acta, 1977, 21, 223-227.	1.2	13
529	Carbonic Anhydrase Inhibitors: Novel Compounds Containing S-NH Moieties: Sulfenamido-Sulfonamides, Sulfenimido-Sulfonamides and their Interaction with Isozymes I, II and IV. Journal of Enzyme Inhibition and Medicinal Chemistry, 1998, 13, 419-442.	0.5	13
530	Carbonic anhydrase inhibitors. Part 60##See ref.Â[1]. The topical intraocular pressure-lowering properties of metal complexes of a heterocyclic sulfonamide: influence of the metal ion upon biological activity. European Journal of Medicinal Chemistry, 1999, 34, 585-595.	2.6	13
531	Carbonic anhydrase inhibitors â€“ Part 78. Synthesis of water-soluble sulfonamides incorporating Î²-alanyl moieties, possessing long lasting-intraocular pressure lowering properties via the topical route. European Journal of Medicinal Chemistry, 2000, 35, 309-321.	2.6	13
532	Carbonic Anhydrase Inhibitors, Interaction of Boron Derivatives with Isozymes I and II: A New Binding Site for Hydrophobic Inhibitors at the Entrance of the Active Site as shown by Docking Studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 125-133.	0.5	13
533	The generation of a 1-hydroxy-2-naphthoate 1,2-dioxygenase by single point mutations of salicylate 1,2-dioxygenase â€“ Rational design of mutants and the crystal structures of the A85H and W104Y variants. Journal of Structural Biology, 2012, 180, 563-571.	1.3	13
534	Sulfonamide inhibition studies of the Î³-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1253-1259.	1.0	13
535	Dioxygen, an unexpected carbonic anhydrase ligand. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 999-1005.	2.5	13
536	Carbonic Anhydrase Activators. , 2004, , 317-352.		13
537	Proton relaxation of water solutions containing copper carbonic anhydrase. Inorganica Chimica Acta, 1977, 23, L15-L16.	1.2	12
538	A 31 P NMR study of phosphate in presence of cobalt(II)- and copper(II)-substituted bovine carbonic anhydrase B. FEBS Letters, 1978, 93, 251-254.	1.3	12
539	Characterization of oxovanadium(IV) substituted bovine carbonic anhydrase B. Inorganica Chimica Acta, 1979, 36, 9-12.	1.2	12
540	1H NMR studies of Chromatium vinosum cytochrome câ€². Archives of Biochemistry and Biophysics, 1990, 282, 84-90.	1.4	12

#	Article	IF	Citations
541	Substrate, substrate analogue, and inhibitor interactions with the ferrous active site of catechol 2,3-dioxygenase monitored through XAS studies. FEBS Letters, 1994, 350, 207-212.	1.3	12
542	Crystallization and preliminary crystallographic analysis of the hydroxyquinol 1,2-dioxygenase from Nocardioides simplex 3E: a novel dioxygenase involved in the biodegradation of polychlorinated aromatic compounds. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 901-903.	2.5	12
543	Protease inhibitors â€“ Part 3. Synthesis of non-basic thrombin inhibitors incorporating pyridinium-sulfanilylguanidine moieties at the P1 site. European Journal of Medicinal Chemistry, 1999, 34, 939-952.	2.6	12
544	Carbonic Anhydrase Inhibitors: Allylsulfonamide, Styrene Sulfonamide, N -allyl Sulfonamides and Some of Their Si, Ge, and B Derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 475-489.	0.5	12
545	Synthesis of rhodamine Bâ€“benzenesulfonamide conjugates and their inhibitory activity against human Î±- and bacterial/fungal Î²-carbonic anhydrases. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5210-5213.	1.0	12
546	Sulfonamide inhibition studies of the Î² carbonic anhydrase from Drosophila melanogaster. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2797-2801.	1.0	12
547	Carbonic Anhydrase Inhibitors in Dermatology. , 2004, , 303-315.		12
548	Interactions between Î±-amino acids and cobalt(II) bovine-carbonic anhydrase. Bioinorganic Chemistry, 1977, 7, 225-231.	1.2	11
549	Stereochemistry of cobalt(II) in cobalt bovine carbonic anhydrase and its derivatives. Inorganica Chimica Acta, 1977, 22, L23-L24.	1.2	11
550	A thermodynamic and spectroscopic study of the complexes of the undecapeptide Substance P, of its N-terminal fragment and of model pentapeptides containing two prolyl residues with copper ions. Journal of the Chemical Society Dalton Transactions, 1991, , 1651.	1.1	11
551	Carbonic Anhydrase Inhibitors. Part 551 Metal Complexes of 1,3,4-Thiadiazole-2-Sulfonamide Derivatives: In Vitro Inhibition Studies With Carbonic Anhydrase Isozymes I, II and IV. Metal-Based Drugs, 1998, 5, 103-114.	3.8	11
552	Arylsulfonyl-N,N-dialkyl-dithiocarbamates as Tumor Cell Growth Inhibitors: Novel Agents Targeting Î²-Tubulin?. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 55-63.	0.5	11
553	Carbonic Anhydrase Inhibitors: Aliphatic N-phosphorylated Sulfamates--A Novel Zinc-anchoring Group Leading to Nanomolar Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 275-278.	2.5	11
554	Carbonic Anhydrase Inhibitors: Binding of Indanesulfonamides to the Human Isoformâ€…II. ChemMedChem, 2008, 3, 473-477.	1.6	11
555	Carbonic anhydrase activators. Activation of the membrane-associated isoform XV with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3430-3433.	1.0	11
556	QSAR studies for the inhibition of the transmembrane carbonic anhydrase isozyme XIV with sulfonamides using PRECLAV software. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 337-349.	2.5	11
557	Enzymatic decolorization of spent textile dyeing baths composed by mixtures of synthetic dyes and additives. Applied Microbiology and Biotechnology, 2012, 96, 395-405.	1.7	11
558	X-ray structures of 4-chlorocatechol 1,2-dioxygenase adducts with substituted catechols: New perspectives in the molecular basis of intradiol ring cleaving dioxygenases specificity. Journal of Structural Biology, 2013, 181, 274-282.	1.3	11

#	Article	IF	Citations
559	Sulfonamide carbonic anhydrase inhibitors: Zinc coordination and tail effects influence inhibitory efficacy and selectivity for different isoforms. Inorganica Chimica Acta, 2018, 470, 128-132.	1.2	11
560	Ligand Field Parameters. Israel Journal of Chemistry, 1976, 15, 189-199.	1.0	10
561	Different behavior of sulfonamides with respect to copper-substituted bovine and human carbonic anhydrases. Journal of Inorganic Biochemistry, 1982, 16, 155-160.	1.5	10
562	Complexes With Biologically Active Ligands. Part 91 Metal Complexes of 5-Benzoylamino- and 5-(3-Nitrobenzoyl-Amino)-1,3,4-Thiadiazole-2-Sulfonamide as Carbonic Anhydrase Inhibitors. Metal-Based Drugs, 1997, 4, 1-7.	3.8	10
563	1H NMR ganglioside ceramide resonance region on the differential diagnosis of low and high malignancy of brain gliomas. Cellular and Molecular Neurobiology, 1997, 17, 521-535.	1.7	10
564	Carbonic Anhydrase Inhibitors Part 721 Synthesis and Antiglaucoma Properties of Metal Complexes of p-Fluorobenzolamide. Metal-Based Drugs, 1999, 6, 67-73.	3.8	10
565	Density Functional Description of the Early Stages of the Dioxygenation of [(MeC(CH2PPh2)3)M(catecholate)]+Complexes [M = Co(III), Ir(III)]:Â Toward a Rationalization of the Catalytic Mechanism of Ring-Opening Dioxygenases. Inorganic Chemistry, 2000, 39, 1418-1425.	1.9	10
566	Crystal analysis of aromatic sulfonamide binding to native and (Zn)2 adduct of human carbonic anhydrase I Michigan 1. Inorganica Chimica Acta, 2002, 339, 135-144.	1.2	10
567	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4282-4286.	1.0	10
568	Structural modulation of the biological activity of gold nanoparticles functionalized with a carbonic anhydrase inhibitor. European Physical Journal E, 2013, 36, 48.	0.7	10
569	Cyclodextrin complexation highly enhances efficacy of arylsulfonylureido benzenesulfonamide carbonic anhydrase inhibitors as a topical antiglaucoma agents. Bioorganic and Medicinal Chemistry, 2015, 23, 6223-6227.	1.4	10
570	Evidence of exchangeable protons in the acidic form of manganese(II) bovine carbonic anhydrase B. FEBS Letters, 1978, 87, 92-94.	1.3	9
571	CD and EXAFS study of the interaction between phosvitin and copper(II) ions. Journal of Inorganic Biochemistry, 1988, 34, 221-239.	1.5	9
572	Direct micellar systems as a tool to improve the efficiency of aromatic substrate conversion for fine chemicals production. Journal of Inorganic Biochemistry, 2000, 79, 103-108.	1.5	9
573	Carbonic Anhydrase Inhibitors; Phosphoryl-Sulfonamides-A New Class of High Affinity Inhibitors of Isozymes I and II. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 297-309.	0.5	9
574	Purification and inhibition studies with anions and sulfonamides of an Î±-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii. Bioorganic and Medicinal Chemistry, 2011, 19, 1847-1851.	1.4	9
575	The electronic spectra of cobalt(II) bovine carbonic anhydrase. Inorganica Chimica Acta, 1979, 36, L431-L432.	1.2	8
576	EXAFS investigation on the iron(III) binding sites of hen phosvitin. Inorganic Chemistry, 1990, 29, 124-127.	1.9	8

#	Article	IF	Citations
577	EXAFS studies of Fe(III)-phosvitin at high metal to protein ratios. BioMetals, 1994, 7, 104-8.	1.8	8
578	Sulfonylamido Derivatives of 2-Aminophenoxathiin-10,10-Dioxide and Related Compounds Possess Antifungal Action Due to the Possible Inhibition of Lanosterol-14-Î±-Demethylase. Journal of Enzyme Inhibition and Medicinal Chemistry, 1998, 13, 291-310.	0.5	8
579	Carbonic Anhydrase Inhibitors: Synthesis and Inhibition Against Isozymes I, II and IV of Topically Acting Antiglaucoma Sulfonamides Incorporatingcis-5-Norbornene-endo-3-Carboxy-2-Carboxamido Moieties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 113-123.	0.5	8
580	Redox State and Carbonic Anhydrase Isozyme IX Expression in Human Renal Cell Carcinoma: Biochemical and Morphological Investigations. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 287-291.	2.5	8
581	Carbonic anhydrase inhibitors. Inhibition of red blood cell ostrich (Struthio camelus) carbonic anhydrase with a series of aromatic and heterocyclic sulfonamides. Journal of Enzyme Inhibition and Medicinal Chemistry, 2005, 20, 383-387.	2.5	8
582	Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5892-5896.	1.0	8
583	Application of 2D1H NMR spectroscopy to the study of the brain, spinal cord, and sciatic nerve. Molecular and Chemical Neuropathology, 1993, 19, 1-13.	1.0	7
584	The role of the active site amino acid residues on the catalytic activity of Cu2Zn2SOD. Molecular and Chemical Neuropathology, 1993, 19, 193-204.	1.0	7
585	Characterization of the biological conversion of naphthalene to (+)-cis-(1R,2S)-dihydroxy-1,2-dihydronaphthalene in direct micellar systems. Journal of Molecular Catalysis B: Enzymatic, 1999, 7, 263-272.	1.8	7
586	Nonionic Micelles Promote Whole Cell Bioconversion of Aromatic Substrates in an Aqueous Environment. Langmuir, 2002, 18, 6015-6020.	1.6	7
587	Carbonic anhydrase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozymes I and II with some 1,3,4-oxadiazole-thiols. Journal of Enzyme Inhibition and Medicinal Chemistry, 2006, 21, 351-359.	2.5	7
588	Carbonic anhydrase inhibitors: The very weak inhibitors dithiothreitol, Î²-mercaptoethanol, tris(carboxyethyl)phosphine and threitol interfere with the binding of sulfonamides to isozymes II and IX. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1898-1903.	1.0	7
589	Ytterbium(III) as a CD probe for the investigation of the metal binding sites of transferrins. Inorganica Chimica Acta, 1986, 124, L15-L17.	1.2	6
590	Functionalized Derivatives of Benzo-Crown Ethers. Part 4. Antifungal Macrocyclic Supramolecular Complexes of Transition Metal Ions Acting as Lanosterol-14-Î± -Demethylase Ihibitors. Metal-Based Drugs, 1999, 6, 101-110.	3.8	6
591	Density Functional Characterization of the Chemoselective Oxidation of Catechol by using Molecular Oxygen: Thermodynamics of the Reaction between [(triphos)Ir(dtbc)]+ and O2. Chemistry - A European Journal, 2003, 9, 3015-3023.	1.7	6
592	Crystallization and preliminary structure analysis of the blue laccase from the ligninolytic fungusPanus tigrinus. Acta Crystallographica Section F: Structural Biology Communications, 2005, 61, 205-207.	0.7	6
593	Crystallization and preliminary X-ray crystallographic analysis of the small subunit of the heterodimeric laccase POXA3b fromPleurotus ostreatus. Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 76-79.	0.4	6
594	Polyamines and Î±-Carbonic Anhydrases. Molecules, 2016, 21, 1726.	1.7	6

#	Article	IF	Citations
595	Carbonic Anhydrase Activators. , 0, , .		6
596	A comment on the Jahn-Teller effect in the complex K2PbCu(NO2)6. Inorganica Chimica Acta, 1975, 13, L5-L6.	1.2	5
597	Single crystal polarized electronic spectra of the complex bis(N-t-butylpyrrole-2-carbaldimino)cobalt(II). Inorganica Chimica Acta, 1975, 13, 145-148.	1.2	5
598	13C Nmr spectra of hexakis pyridine-N-oxide cobalt(II) and nickel(II) complexes. Inorganica Chimica Acta, 1976, 19, 201-202.	1.2	5
599	31P NMR spectra of paramagnetic MBr2 (OPPh3)2 complexes. A breakdown in the validity of the Solomon-Bloembergen equations. Inorganic and Nuclear Chemistry Letters, 1979, 15, 89-91.	0.7	5
600	Intramolecular ring-stacking interaction between caffeine and bis(1,10-phenanthroline)copper(II) ion: 1H NMR and calorimetric investigations. Inorganica Chimica Acta, 1981, 56, 73-77.	1.2	5
601	Cooperative phenomena in polynuclear metalloproteins. Inorganica Chimica Acta, 1982, 62, 15-22.	1.2	5
602	Investigation of the copperî—¸magnesiumî—¸alkaline phosphatase system. Inorganica Chimica Acta, 1983, 78, 19-22.	1.2	5
603	Investigation of zinc-deprived bovine superoxide dismutase. Inorganica Chimica Acta, 1984, 91, 109-111.	1.2	5
604	Copper-cobalt superoxide dismutase: A re-examination of the1H NMR spectrum through a novel selectively deuteriated derivative. Magnetic Resonance in Chemistry, 1993, 31, S17-S22.	1.1	5
605	Protease Inhibitors. Part 2. Weakly Basic Thrombin Inhibitors Incorporating Sulfonyl-Aminoguanidine Moieties as S1 Anchoring Groups: Synthesis and Structure-Activity Correlations. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 235-264.	0.5	5
606	4-Chlorocatechol 1,2-dioxygenase from the chlorophenol-utilizing Gram-positiveRhodococcus opacus1CP: crystallization and preliminary crystallographic analysis. Acta Crystallographica Section D: Biological Crystallography, 2002, 58, 1074-1076.	2.5	5
607	Experimental and theoretical affinity studies of substituted phenols to chlorocatechol 1,2-dioxygenases: A step toward the comprehension of inhibitor/substrate binding to intradiol dioxygenases. Journal of Molecular Catalysis B: Enzymatic, 2010, 64, 53-59.	1.8	5
608	Carbonic anhydrase inhibitors: Gd(iii) complexes of DOTA- and TETA-sulfonamide conjugates targeting the tumor associated carbonic anhydrase isozymes IX and XII. New Journal of Chemistry, 2010, 34, 2139.	1.4	5
609	Complexes between pilocarpine and cobalt(II), nickel(II), copper(II), and zinc(II) Ions. Journal of Pharmaceutical Sciences, 1980, 69, 1220-1222.	1.6	4
610	INTERACTION OF ISOZYMES I AND II OF CARBONIC ANHYDRASE WITH Ge(IV) AND Sb(lll) DERIVATIVES. Main Group Metal Chemistry, 1997, 20, .	0.6	4
611	Carbonic Anhydrase Inhibitors. Part 541: Metal Complexes of Heterocyclic Sulfonamides: A New Class of Antiglaucoma Agents. Metal-Based Drugs, 1997, 4, 307-315.	3.8	4
612	The Antifungal Activity of 2,2 -Diamino-4,4 -Dithiazole Derivatives is Due to the Possible Inhibition of Lanosterol-14â€“Î±-Demethylase. Journal of Enzyme Inhibition and Medicinal Chemistry, 1998, 14, 49-68.	0.5	4

#	Article	IF	Citations
613	Complexes With Biologically Active Ligands. Part 111. Synthesis and Carbonic Anhydrase Inhibitory Activity of Metal Complexes of 4,5-Disubstituted-3-Mercapto-1,2,4-Triazole Derivatives. Metal-Based Drugs, 1998, 5, 11-18.	3.8	4
614	Protease Inhibitors, Part 13: Specific, Weakly Basic Thrombin Inhibitors Incorporating Sulfonyl Dicyandiamide Moieties in their Structure. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 1-13.	0.5	4
615	Carbonic Anhydrase Activity Modulators: Synthesis of Inhibitors and Activators Incorporating 2-substituted-thiazol-4-yl-methyl Scaffolds. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 351-358.	0.5	4
616	Preliminary crystallographic analysis of 3-chlorocatechol 1,2-dioxygenase of a new modifiedortho-pathway from the Gram-positiveRhodococcus opacus1CP grown on 2-chlorophenol. Acta Crystallographica Section D: Biological Crystallography, 2003, 59, 188-190.	2.5	4
617	The crystal structures of native hydroquinone 1,2-dioxygenase from Sphingomonas sp. TTNP3 and of substrate and inhibitor complexes. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 520-530.	1.1	4
618	X-ray and ESR investigation of an elongated octahedral tris-(1, 2-diaminoethane) copper (II) complex. Solid State Communications, 1978, 26, 749-751.	0.9	3
619	Multinuclear NMR investigation of the metal binding sites of transferrins. Journal of Molecular Structure, 1984, 113, 191-200.	1.8	3
620	Carbonic Anhydrase Activators. Part 191 Spectroscopic and Kinetic Investigations for the Interaction of Isozymes I and II With Primary Amines. Metal-Based Drugs, 1997, 4, 221-227.	3.8	3
621	Synthesis and Antifungal Activity of Metal Complexes Containing Dichloro-Tetramorpholino-Cyclophosphazatriene. Metal-Based Drugs, 1998, 5, 287-294.	3.8	3
622	INHIBITION OF CARBONIC ANHYDRASE ISOZYMES I, II AND IV WITH ARSINOLIPIDS. Main Group Metal Chemistry, 1999, 22, .	0.6	3
623	The Antifungal Activity of Sulfonylated/Carboxylated Derivatives of Dibenzo-1,4-Dioxine-2-Acetyloxime May Be Due to Inhibition of Lanosterol-14Al-Demethylase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 557-569.	0.5	3
624	Carbonic anhydrase inhibitors. N-Cyanomethylsulfonamidesâ€"a new zinc binding group in the design of inhibitors targeting cytosolic and membrane-anchored isoforms. Journal of Enzyme Inhibition and Medicinal Chemistry, 2006, 21, 477-481.	2.5	3
625	Crystallization and preliminary X-ray crystallographic analysis of hydroquinone dioxygenase fromSphingomonassp. TTNP3. Acta Crystallographica Section F: Structural Biology Communications, 2012, 68, 588-590.	0.7	3
626	Protease Inhibitors: Part 4. Synthesis of Weakly Basic Thrombin Inhibitors Incorporating Pyridinium-Sulfanilylaminoguanidine Moieties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 335-356.	0.5	2
627	X-ray crystallographic and molecular docking studies on a unique chloromuconolactone dehalogenase from Rhodococcus opacus 1CP. Journal of Structural Biology, 2013, 182, 44-50.	1.3	2
628	Structural basis for the substrate specificity and the absence of dehalogenation activity in 2-chloromuconate cycloisomerase from Rhodococcus opacus 1CP. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1541-1549.	1.1	2
629	Some Structural Aspects of Carbonic Anhydrase. Proceedings in Life Sciences, 1980, , 151-153.	0.5	2
630	INHIBITION OF CARBONIC ANHYDRASE ISOZYMES I, II AND IV WITH ARSANILIC ACID DERIVATIVES. Main Group Metal Chemistry, 1998, 21, .	0.6	1

#	Article	IF	Citations
631	Mechanism of action of carbonic anhydrase inhibitors. , 2019, , 245-255.		1
632	Treatment of NSAPs-rich petrochemical wastewaters using a two-stage combined process of fungi and activated sludge. Environmental Technology (United Kingdom), 2020, 42, 1-14.	1.2	1
633	Iron-sulfur Proteins: Part II Valence-specific Assignment in Oxidized Hipip through 1H NMR Spectroscopy. Topics in Molecular Organization and Engineering, 1994, , 143-157.	0.1	1
634	spectroscopic Investigation on a New Class of Inhibitors which Bind either the Acidic or Basic Form of Cobalt Substituted Carbonic Anhydrase. Inorganica Chimica Acta, 1980, 40, X86.	1.2	0
635	Carbonic Anhydrase Inhibitors. ChemInform, 2003, 34, no.	0.1	0
636	Carbonic Anhydrase Inhibitors: Inhibition of Cytosolic Isozymes I and II with Sulfamide Derivatives.. ChemInform, 2003, 34, no.	0.1	0
637	Carbonic Anhydrase Inhibitors: Topically Acting Antiglaucoma Sulfonamides Incorporating Esters and Amides of 3- and 4-Carboxybenzolamide.. ChemInform, 2003, 34, no.	0.1	0
638	Protease Inhibitors of the Sulfonamide Type: Anticancer, Antiinflammatory, and Antiviral Agents. ChemInform, 2003, 34, no.	0.1	0
639	Carbonic Anhydrase Inhibitors: Inhibition of the Tumor-Associated Isozyme IX with Fluorine-Containing Sulfonamides. The First Subnanomolar CA IX Inhibitor Discovered.. ChemInform, 2004, 35, no.	0.1	0
640	Carbonic Anhydrase Inhibitors. Novel Sulfanilamide/Acetazolamide Derivatives Obtained by the Tail Approach and Their Interaction with the Cytosolic Isozymes I and II, and the Tumor-Associated Isozyme IX.. ChemInform, 2005, 36, no.	0.1	0
641	Sulfamates and Their Therapeutic Potential. ChemInform, 2005, 36, no.	0.1	0
642	Carbonic Anhydrase Inhibitors: Synthesis and Inhibition of Cytosolic/Tumor-Associated Carbonic Anhydrase Isozymes I, II, and IX with Sulfonamides Incorporating Thioureido-Sulfanilyl Scaffolds.. ChemInform, 2005, 36, no.	0.1	0
643	Carbonic Anhydrase Inhibitors: Synthesis and Inhibition of Cytosolic/Tumor-Associated Carbonic Anhydrase Isozymes I, II, IX, and XII with N-Hydroxysulfamides â€" A New Zinc-Binding Function in the Design of Inhibitors.. ChemInform, 2005, 36, no.	0.1	0
644	Carbonic Anhydrase Inhibitors: Design of Thioureido Sulfonamides with Potent Isozyme II and XII Inhibitory Properties and Intraocular Pressure Lowering Activity in a Rabbit Model of Glaucoma.. ChemInform, 2005, 36, no.	0.1	0
645	Protease Inhibitors: Synthesis of Matrix Metalloproteinase and Bacterial Collagenase Inhibitors Incorporating 5â€Aminoâ€2â€mercaptoâ€1,3,4â€thiadiazole Zinc Binding Functions.. ChemInform, 2002, 33, 141-141.	0.1	0
646	Heterocyclic compounds and their uses: a patent evaluation of WO2010151735A2. Expert Opinion on Therapeutic Patents, 2011, 21, 803-806.	2.4	0
647	Heterocyclic urea derivatives and methods of use thereof (WO2010142978). Expert Opinion on Therapeutic Patents, 2012, 22, 193-197.	2.4	0
648	Predictive Models for the Efficacy of Bioremediation. , 1997, , 25-37.		0